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Tissue engineering strategies incorporate cells and bioactive cues within a synthetic scaffold to 
mimic the biophysical and biochemical properties of native tissue to regenerate or repair damaged 
tissues and organs. A major challenge within tissue engineering is the use of supraphysiological 
doses of growth factors as bioactive cues to direct regeneration. The high concentrations of growth 
factors are often necessary for successful tissue regeneration due to short half-lives and protease 
degradation of growth factors; however, supraphysiological doses of growth factors have resulted 
in negative complications such as uncontrolled tissue growth, or cancer. To overcome this 
challenge, we have integrated cell biology, materials science, and bioengineering to develop a 
nanosilicate-based platform which can significantly reduce and potentially eliminate growth factor 
incorporation. Nanosilicates ([Na+0.7[(Mg5.5Li0.3)Si8O20(OH)4]
-0.7, Laponite XLG) are two-
dimensional, charged particles with unique biochemical and biophysical properties. Here, we 
develop and utilize this platform for orthopedic tissue regeneration, establishing the unique 
properties of nanosilicates including their inherent bioactivity, ability to sequester and sustain 
release of therapeutic proteins, and incorporation into bioactive hydrogel scaffolds. Specifically, 
we utilize whole-transcriptome sequencing (RNA-seq) to holistically view human mesenchymal 
stem cell (hMSC) responses after treatment with nanosilicates to evaluate potential for stimulating 
both osteogenic and chondrogenic differentiation of hMSCs. We further investigated the 
mechanisms behind the innate bioactivity and reveal ionic dissolution products of nanosilicates 
(Li+, Mg2+, Si(OH)4) stimulate osteogenesis in hMSCs. In addition to their inherent 




growth factors for prolonged duration to demonstrate enhanced osteogenic differentiation in 
hMSCs. Finally, as we assess the potential of nanosilicate-based scaffolds for regeneration of 
interface osteochondral tissues by fabricating a gradient hydrogel. We show that cell morphology 
can be modulated along the gradient without the use of external growth factors. From these studies, 
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Figure 1-1. Orthopedic interface tissues include bone-cartilage, tendon-bone, and ligament-
bone interfaces. In all these interfaces, a gradual transition in structure, chemical 
composition, and cell types between the two tissues are observed. The cartilage, 
tendon, and ligament are collagenous soft tissues, whereas bone consists of 
mineralized collagen. ...................................................................................................... 4 
Figure 1-2. Engineering approaches for interface tissue engineering. Several strategies 
including use of monolithic, layered and gradient scaffolds are investigated to mimic 
the native tissue interfaces. Monolithic scaffolds comprise of one type of biomaterial 
loaded with cells, whereas layered scaffolds comprise different layers, each 
representing a single tissue type. Multi-layered scaffolds employ the middle layer, 
which represents the interface region. The gradient scaffold accounts for the interface 
region and the smooth transition between two regions. .................................................. 8 
Figure 1-3. Nanocomposite scaffolds for osteochondral regeneration. (a) SEM show uniform 
distribution of nHAp in agarose gel and presence of calcium (Ca) and phosphorous 
(P) is confirmed by EDS and FTIR analysis. No significant effect of nHAp on elastic 
modulus and shear modulus is observed. (b) The effect of micro and nano HA 
particles on GAG and collagen show a significant increase on day 14. Also, the 
addition of particles leads to a significant increase in ALP activity, production of type 
X collagen and Ihh expression on day 14. (c) The cell-loaded scaffolds have 
significantly higher mechanical stiffness compared to the acellular scaffolds. Linear 
correlation analysis shows a positive relationship between GAG content and 
compressive modulus and shear modulus for all scaffolds. Finally, to determine 
synergistic affects, a significant correlation of GAG + collagen with the nano and 
micro HA groups is observed. Reproduced with permission.(79) Copyright © 2012, 
Elsevier B.V. and Copyright © 2012, Mary Ann Liebert, Inc. ..................................... 13 
Figure 1-4 Bilayered nanocomposite scaffolds for osteochondral regeneration. (a) Synthesis of 
bilayered silk/silk-nCaP scaffold (top) and subsequent implantation in rabbit model 
(bottom). (b) SEM and EDS analysis of the layered scaffold investigates presence of 
calcium in different zones (Z1-4). (c) CaP distribution investigated using micro-CT, 
showing two distinct layers - silk layer (brown) and composite layer (blue). (d) 
Quantitative analysis of porosity distribution shows homogeneous and interconnected 
porous network in each layer. (e) In vivo studies reveal type II collagen (red) 
production in the silk layer of the scaffold (bottom left), while the control defect does 




formation is present at the edge of the top silk layer (bottom right) but is not present 
in the control defect (top right); the S refers the scaffold and the arrow points to newly 
formed tissue. Reproduced with permission.(56) Copyright © 2012, Elsevier B.V. .... 17 
Figure 1-5. Emerging trends in interface tissue engineering. (a) Bioactive nanomaterials such 
as ceramic, metal oxides and 2D nanomaterials have potential to control and trigger 
cellular process. (b) Microarray printing technology can be used to screen 
nanomaterials library in a high-throughput manner. (c) Bioprinting techniques can be 
used to engineering layered scaffold for orthopedic tissue interfaces. (d) The use of a 
3D bioprinter can mimic native tissue architecture with high spatiotemporal control 
of cells and physical/chemical clues. ............................................................................ 20 
 
Figure 2-1 Physical characterization of nanosilicates was completed to evaluate particles before 
introducing to hMSCs. (A) TEM of nanosilicates demonstrated disk morphology and 
nanoscale size. (B) XPS analysis revealed an elemental composition similar to that of 
the idealized stoichiometric ratio found within a unit cell of the nanosilicates. (C) 
AFM corroborated the nanoscale diameter (25-50 nm) and thickness (1-1.5 nm) of 
the nanosilicate. (D) XRD of both bulk and exfoliated (flash frozen with subsequent 
lyophilization) nanosilicates generated peaks at diffraction planes (001), (100), and 
(005) for both, with (110) and (300) present in bulk sample. (E) DLS measurements 
quantified variability of nanosilicates hydrodynamic size in particles and displayed a 
narrow range of diameters (polydispersity index, 0.22) around 45 nm. ....................... 37 
Figure 2-2 Nanosilicates effect on cellular processes. (A) Metabolic activity, assessed via MTT 
assay, remained unaffected by nanosilicate introduction at bioactive concentrations. 
Minimal effect of nanosilicates was observed on cell health monitored via (B) Alamar 
blue assay, (C) cytoskeletal organization, and (D) cell cycle analysis. ........................ 39 
Figure 2-3 Biophysical interaction of nanosilicates and hMSCs. (A) Two-dimensional 
nanosilicates electrostatically bind to proteins from biological fluids and are 
subsequently internalized by cells via surface-mediated endocytosis. (B) 
Hyperspectral imaging indicating distribution of nanosilicates throughout the cell 
body following endocytosis. The image was captured from transverse section of cell 
body. (C) Flow cytometry analysis of rhodamine-tagged nanosilicates demonstrate 
dose-dependent cellular uptake. The nanosilicates were primarily internalized via 
clathrin-mediated process (chlorpromazine) as opposed to micropinocytosis 
(wortmannin) or caveolar-mediated (nystatin). **P-value < 0.01; ***P-value < 0.001. 
(D) LAMP1 staining (green) for lysosomal membranes further tracks nanosilicates 
(red) following endocytosis. (F) Row-scaled z-scores of quantile normalized gene 
expression [in log2(RPKM)] of >4000genes following treatment with nanosilicates 
(padjust < 0.5, red, up-regulated: 1,897 genes; blue, down-regulated: 2,171 genes). 
(G) Significant gene ontology (GO) terms of associated biological processes, cellular 
components, and molecular functions from differentially regulated genes (P < 0.5). 
Terms related to biological process and cellular components indicate strong 




244 cellular component GO terms into broader cellular component categories. (H) 
Gene network displaying interconnected genetic targets after nanosilicate treatment 
with high degrees of expression and statistical significance (red, up-regulated; blue, 
down-regulated; size increases with significance). ....................................................... 41 
Figure 2-4 Nanosilicates interactions with hMSCs were monitored using flow cytometry and 
ICP-MS. (A) Uptake of fluorescently tagged nanosilicates displayed concentration-
dependent internalization. (B) Endocytosis of particles occurred rapidly with 
chemical inhibition of a clathrin-mediated process reducing uptake. (C) Following 
internalization, tagged particles were trafficked to lysosomal bodies with an increase 
in these vesicles observed after 24 hours and returning to basal levels over the course 
of a week. (D) Introduction of nanosilicates to low-pH environments of late 
endosome/lysosome vesicles initiated dissolution of the particles over a week. Ion 
products were greatest at 24 hours and decreased over time as nanosilicates continued 
to be trafficked in and out of the cell in addition to particle dissociation. .................... 43 
Figure 2-5 Nanosilicates lead to stress-induced MAPK signaling. (A) Nanosilicate treatment 
results in activation of stress-related response. A list of significant GO terms related 
to stress after nanosilicate treatment indicate signal propagation via MAPK/ERK 
signaling pathways. (B) The majority of genes involved in stress-activated kinase 
signaling cascade (GO:0031098) undergo a significant differential expression. (C) 
The change in gene expression profile of MAP4K4 and TAOK1 (aligned reads 
normalized by total library size). (D) Comparison of TAOK1 gene expression 
obtained from RNA-seq was validated using qRT-PCR. (E) Nanosilicates trigger a 
stress-responsive kinase cascade (Ras-Raf-MEK-ERK pathways), leading to changes 
in reactive oxygen species (ROS) production and subsequent RNA transcription and 
protein synthesis. (F) Flow-cytometric analysis was performed to measure the stress-
responsive kinase cascade, by measuring ROS production with ROS-sensitive 
fluorescent reporter dye. Experiments were performed in the presence or absence of 
a MAPK inhibitor. A significant increase in ROS-mediated fluorescent signal is 
observed upon exposure to nanosilicates, and this is abrogated after treatment with 
the MAPK inhibitor. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (G) 
Production of p-MEK1/2 was determined using Western blot in presence of 
nanosilicates and MEK inhibitor, establishing the role of nanosilicates in MAPK/ERK 
signaling. *P <0.05. ns, not significant. ........................................................................ 49 
Figure 2-6 Transcriptomic analysis elucidates nanosilicate-induced bioactivity. (A) GO terms 
related to osteogenesis and chondrogenesis indicate nanosilicate-induced hMSC 
differentiation. (B) Significant gene expression changes in genes involved in bone 
development (GO:0060348) and cartilage development (GO:0060351). (C) Gene 
expression profile of COMP, COL11A1, and ACAN, demonstrating up-regulation due 
to nanosilicate treatment (aligned reads normalized by library size). (D) Differential 
gene expression from RNA-seq was validated using qRT-PCR, indicating similar 




Figure 2-7 Nanosilicate-induced hMSC differentiation. (A) Western blot showing production 
of COL1A1 and COMP after exposure to nanosilicates for 7 days in normal media. 
(B) The effect of nanosilicates on production of GAGs was determined by safranin O 
and aggrecan staining after culturing hMSCs in chondro-conductive media for 21 
days. (C) The effect of nanosilicates on osteogenic differentiation was determined by 
ALP activity and formation of mineralized matrix after culturing hMSCs in osteo-
conductive media for 21 days. *P < 0.05; ***P < 0.001; ****P <0.0001; n, not 
significant. ..................................................................................................................... 54 
 
Figure 3-1 Nanosilicate dissociation at physiological pH. (a) Nanosilicates begin to dissociate 
at pH<9 so once introduced to the extracellular (pH 7.4) and intracellular (pH 5.5) 
microenvironment, ion dissociation occurs. (b) Silicon, lithium, and magnesium ion 
release was monitored via ICP-MS, revealing significant dissociation at pH 7.4 and 
5.5 compared to pH 10 where nanosilicates remain stable. .......................................... 65 
Figure 3-2 (a) hMSC viability at various mineral ion concentrations. Concentrations of released 
ions fall well below IC50 value. (b) Long-term hMSC viability after ion treatment 
assessed via Alamar blue assay. .................................................................................... 67 
Figure 3-3 hMSC osteogenic differentiation. (a) ALP and matrix mineralization production 
after treatment with ions for 7, 14 and 21 days (Scale bar 500 µm). (b) ALP activity 
of individual ions compared to nanosilicates and all ions. (c) Quantification of 
mineralized matrix after 21 days. (d) Western blot of osteo-specific proteins after 14 
days. (e) Quantification of protein expression from western blot normalized to β-actin 
expression. *P-value < 0.05**P-value < 0.01, ***P-value <0.001, ****P-value 
<0.0001 .......................................................................................................................... 70 
Figure 3-4 Comparison of genetic expression between different hMSC treatment groups. (a) 
Gene expression evaluated via qRT-PCR after 14 days, fold-change compared to 
untreated hMSCs. (b) Principal component analysis graph displaying genetic 
distance/relatedness across different ion and nanosilicate treatments. (c) Heat map 
visualizing genetic variation between different ion treated hMSCs compared to 
nanosilicate-treated hMSCs. .......................................................................................... 72 
 
Figure 4-1 Physical characterization of nanosilicates. (a) TEM revealed size of two-dimensional 
nanosilicates. (b) AFM indicated the thickness of nanosilicates ~1-2 nm. (c) ATR-
FTIR showed characteristic peaks at ~1000 and 700 nm representing Si-O bending 
and stretching, respectively. (d) XPS showed chemical composition of nanosilicates 
as shown by the binding energies for oxygen, silicon, magnesium, lithium, and 
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Figure 4-2 Nanosilicates strongly interact with proteins. (a) Schematic of protein interactions 
with nanosilicates. TEM images of nanosilicates in fetal bovine serum (FBS) solution. 




shift in particle size with addition of protein solution. Zeta potential of nanosilicates 
and nanosilicates with FBS; once in contact with protein, particle charge shifts to be 
more positive (***P-value < 0.001). (c) Percent binding efficiency of nanosilicates to 
protein; nearly 100% binding observed at a ratio of nanosilicates to protein of 5:1. (d) 
ANS assay demonstrating no change in protein’s secondary structure when bound to 
nanosilicates as indicated by minimal shift in fluorescent peak compared to 
completely denatured protein (positive control). (e) Early and long-term release of 
protein from nanosilicates. Protein release was monitored for over 30 days. ............... 85 
Figure 4-3 rhBMP2 bound to nanosilicates enhances alkaline phosphatase production. 
Nanosilicates and rhBMP2 bound to nanosilicates were delivered once while 
exogenous rhBMP2 was delivered every media change (every 3-4 days). (a) rhBMP2 
bound to nanosilicates enhances alkaline phosphatase protein production compared 
to exogenous rhBMP2. (b) ALP activity after 7 and 14 days of culture. After 7 days, 
rhBMP2 delivery via nanosilicates increased production significantly (*P-value < 
0.05, **P-value < 0.01, ****P-value < 0.0001. (c) Western blot of ALP after 14 days 
reveals an increase in protein production for groups treated with nanosilicate bound 
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Figure 4-4 Sustained delivery of rhBMP2 promotes osteo-specific protein production. (a) 
Osteocalcin production enhanced by dual delivery of nanosilicates and growth factor 
after 14 days of culture. (b) Western blot of osteocalcin and osteopontin after 14 days 
revealed increase in protein production in all treatment groups compared to the 
control. In addition, collagen type I (Col1A1) production was increased in the 
nanosilicate/rhBMP2 treated hMSCs. (c) Quantification of osteocalcin showed a 
significant increase in exogenous and nanosilicate/rhBMP2 groups compared to the 
control (**P-value < 0.01). In addition, quantification of intensity values for Col1A1 
revealed a significant increase in protein production for nanosilicate/rhBMP2 (****P-
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1. INTRODUCTION*  
 
 
1.1 Introduction to Nanoengineered Biomaterials for Repair or Regeneration of Orthopedic 
Tissue Interfaces 
The musculoskeletal system, also known as the locomotive system, confers the ability to move 
through muscular and skeletal attachments. Major components of this system include connective 
tissues such as bone, tendon, ligament and cartilage. The orthopedic tissue interfaces are classified 
into i) bone-cartilage ii) bone-tendon and iii) bone-ligament, representing a transition from hard to 
soft tissues (Figure 1-1). These interfaces are responsible for the functional interactions between 
the adjoining tissues and reduce the formation of stress epicenters, which result in the load bearing 
flexibility. Most musculoskeletal injuries are associated with these interface regions and are 
common among individuals performing strenuous activities (athletes and military personnel) and 
also result due to ageing. Typical interventions to heal interfacial tissue injuries involve surgical 
procedures, suturing the injured tissues and stabilizing via braces, preventing further movement to 
avoid tearing.(1) However, open surgical interventions suffer major disadvantages such as post-
suture scarring, tumor formation, and limited recovery.(2) To overcome these barriers, a range of 
tissue-engineered approaches have been proposed. 
 
                                                 
* Reprinted with permission from “Cross L.M.; Thakur A.; Jalili N.A.; Detamore M.; Gaharwar 
A.K. Nanoengineered Biomaterials for Repair and Regeneration of Orthopedic Tissue Interfaces. 





A major challenge in engineering interfaces is to control the physical characteristics of an artificial 
environment in terms of structure and mechanical differences: hard and soft regions. The hard 
regions usually represent bone tissues, primarily cortical or cancellous bone. Cortical bone is a 
dense and compact osseous tissue, with a modulus in the range of 16-23 GPa, and forms the outer 
covering of the bone.(3) Its primary function is to provide stability and protect the internal porous 
structures. Cancellous bone, however, is relatively soft due to a higher surface area/mass ratio and 
therefore less dense, with a modulus in the range of 1-2 GPa.(4) Cancellous bone is highly 
vascularized and metabolically active, and also harbors the bone marrow, which forms the site of 
hematopoiesis.(5) The soft regions of the interface are formed from connective tissues such as 
tendon, ligament, and cartilage. Tendons are fibrous tissues that attach skeletal muscles to bones 
(Bone-Tendon-Muscle-Tendon-Bone),(6) whereas ligaments link one bone to another and are 
crucial for joint formation.(7) Both tendon and ligament have a modulus ranging between 0.3-0.8 
GPa. On the contrary, cartilage is the softest among the three, with a modulus of 0.5-2 MPa, and 
is primarily responsible for mitigating friction, compressive, and shear forces between bones.(8, 
9) 
 
Engineering tissue interfaces using biomaterials is a challenge due to complex architecture, cell 
heterogeneity, spatiotemporal distribution of extracellular proteins, and biochemical signals in the 
native tissue interface.(10-12) For example, tendon is a collagenous tissue connecting bone and 
muscles. It is made of parallel running collagen fibers and elongated tenocytes, embedded in 
extrafibrillar matrix.(9) Ligaments are also composed of collagenous fibers loaded with spindle 
shaped fibroblast cells. The ligament can be distinguished into white and yellow ligament based 




serve to facilitate the joint movements, protect bone ends, and restrict incompatible 
movements.(13) For cartilage, the matrix is produced by chondrocytes and is not permeated with 
blood vessels or nerves, as the nutrient exchange occurs through simple diffusion.(14) Due to an 
absence of nerves and blood vessels, regeneration of damaged cartilage tissue is severely hampered 
in ageing and musculoskeletal disorders. In addition, dissimilar properties of bone and other soft 
tissues make it challenging to mimic the native interface tissue using monolithic biomaterials or 
conventional fabrication technologies. A range of comprehensive reviews are available that 
summarize various approaches to engineer interface tissues.(15-23)  
 
Here, we focus on nanoengineered biomaterials and nanofabrication technologies used to mimic 
interface tissue structures and properties (Figure 1-1). Specifically, we critically evaluated various 
nanomaterials that have been employed to engineer bone-cartilage interfaces. We have also 
discussed some of the advanced micro- and nanofabrication tools currently used to engineer 
layered and gradient structures. Here, we capture the current state of nanomaterial research for 
orthopedic interface tissue engineering and identify promising new research directions in the field. 
Specifically, recent developments that are shaping this emerging field of interface tissue 
engineering are highlighted, and some of the newly developed nanomaterials that can be used in 








Figure 1-1. Orthopedic interface tissues include bone-cartilage, tendon-bone, and ligament-bone interfaces. 
In all these interfaces, a gradual transition in structure, chemical composition, and cell types between the 
two tissues are observed. The cartilage, tendon, and ligament are collagenous soft tissues, whereas bone 




1.2 Nanoengineered Biomaterials for Orthopedic Tissue Applications  
Nanoengineered biomaterials and nanofabrication technologies have emerged as an alternative to 
conventional approaches to mimic biological tissues.(24-27) Due to enhanced control over 
structural, mechanical and chemical properties of nanoengineered materials, cells seeded on or 
within these 3D scaffold can help in mimicking some of the biological characteristics of native 
tissue interfaces. For example, various nanofabrication techniques such as electrospinning, and 
phase separation can provide control over the spatial geometry and biological complexity of the 




cellular behavior.(31, 32) Complex geometries such as fibers, spheres, sheets, hollow tubes and 
nets can be fabricated to mimic some of the biological structures. In this review, we only focus on 
nanomaterials with one of their dimensions less than 500 nm. Specifically, we critically evaluate 
different types of nanomaterials currently used for orthopedic interface regeneration.  
 
A range of ceramic and polymeric nanomaterials has been used for engineering orthopedic tissues 
including bone, cartilage, tendon, and ligaments.(20, 27, 29) Ceramic-based nanomaterials 
including hydroxyapatite, calcium phosphate, nanosilicates, and bioactive glasses have been used 
for hard tissues such as bone due to their high bioactive ability.(25-27) The most commonly 
explored nanoparticle for bone regeneration is hydroxyapatite (HAp), which has been extensively 
investigated for orthopedic implants.(33-36) HAp closely resembles biological apatite found in 
bone tissue, and therefore is a desirable biomaterial for bone regeneration. Other bioactive 
materials include use of calcium phosphate, bioactive glasses and silicates. Silicate nanoparticles 
are two-dimensional (2D) nanoparticles that have shown to induce osteogenic differentiation.(37, 
38) When incorporated into hydrogels, the nanosilicates also increased mechanical properties, 
which would allow for the material to be applied to bone scaffolds.(39-41) Although not as 
extensively explored as nHAp, nanosilicates are emerging as a promising material for bone 
regeneration. These ceramic nanoparticles are complex mineral structure that have shown to bind 
to surrounding bone and stimulate bone formation. More recently, a range of carbon-based 
nanomaterials such as carbon nanotubes (CNTs), graphene (G), and nanodiamonds (NDs) have 
also been explored for bone tissue engineering.(42) Graphene has induced osteogenic 






For soft orthopedic tissues such as cartilage, tendons, and ligaments, only a few types of 
nanomaterials have been investigated. For cartilage tissue, titanium dioxide (TiO2) nanosheets 
were explored.(45) These nanosheets were incorporated into an acrylamide hydrogel and the 
resulting nanocomposite mimicked chemical and physical properties of native articular cartilage. 
For tendon and ligament tissues, nanofibers are most often used because of the fibrous structure 
of native tissues. Nanofibers have been fabricated from various polymeric biomaterials including 
poly (lactic-co-glycolic acid) (PLGA), poly (L-lactic acid) (PLLA), poly (caprolactone) (PCL), 
and collagen.(46-50)  
 
Specifically, for interface tissue engineering, many of the aforementioned nanomaterials have not 
been investigated and only a few of the conventional nanomaterials are engineered for interface 
tissue engineering. For example, a range of nanofabrication techniques are used to obtain 
nanoengineered scaffolds from synthetic and natural polymers including PLGA, PLLA, PCL, 
collagen, hyaluronic acid, silk, alginate and fibrin. These biomaterials are usually modified for 
use; in some cases blended with other polymers and nanoparticles (hydroxyapatites, calcium 
phosphate etc.) to enhance the mechanical properties and bioactive characteristics.(25-27) 
Specifically, nanoscale topographies obtained by incorporating nanoparticles in the polymeric 
structure have shown to direct cell fate.(51) In the past couple of decades, the application of 
nanocomposite materials has progressively surfaced since they can stimulate morphological 






1.3 Nanoscale Technologies to Engineer Layered and Gradient Structures 
Several fabrication strategies are currently used to engineer orthopedic interface tissues (Figure 1-
2). The most basic approach involves monolithic scaffolds loaded with growth factors and/or 
cells.(53) This strategy was commonly used when modeling one tissue type such as bone or 
cartilage; however when it comes to interface tissues, this strategy cannot represent multiple tissue 
types. Recently, bi-layered scaffolds have been investigated, where each layer of the scaffold 
represents a different tissue.(54-56) Although a better representation of the complex interface 
tissue, this strategy does not account for the interface region.(19)  
 
More recently, multi-layered scaffolds consisting of three or more layers have been designed. In 
this strategy, the middle layer(s) represents the interface region and the outer layers mimic the soft 
or hard tissue.(57-59) With these layered designs, multiple materials and cell types can be 
incorporated to mimic the complex architectures of the interface tissues; however, there is not 
necessarily a smooth transition between the two represented tissues as there is the body. One of 
the emerging strategies to mimic interface tissues involves developing a gradient scaffold.(19, 21, 
22) In this approach, a gradual change in the material or the chemical composition is engineered 
to better recapitulate the native tissue transition. The gradual change can lead to differential 
expression of cultured cells and give rise to a multifarious environment. Many of the reviewed 
techniques utilized this gradient approach, and the formation of the chemical or material gradient 
can be formed through several methods including capillary action, microfluidics, tilt angle, and 
centrifugation.(22, 23) Here, we highlight the gradient and layered nanofabrication techniques that 








Figure 1-2. Engineering approaches for interface tissue engineering. Several strategies including use of 
monolithic, layered and gradient scaffolds are investigated to mimic the native tissue interfaces. Monolithic 
scaffolds comprise of one type of biomaterial loaded with cells, whereas layered scaffolds comprise 
different layers, each representing a single tissue type. Multi-layered scaffolds employ the middle layer, 
which represents the interface region. The gradient scaffold accounts for the interface region and the smooth 




1.4 Bone-Cartilage Interface 
The aim of interface tissue engineering is to regenerate, augment or repair the damaged interface 
between the bone and its surrounding tissue. Cartilage injuries are often difficult to treat because 
damage can occur in both the articular cartilage and the underlying subchondral bone or more 
specifically the osteochondral interface. Some of the clinically relevant techniques for cartilage 
regeneration involve osteochondral approaches and include chondrocyte and osteochondral 
transplantation, as well as debridement of damaged tissues (through arthroscopy). Often, surgical 
procedures require the removal of the injured bone-cartilage region through the creation of an 
osteochondral defect. Another common surgical procedure for these injures involves 
microfracture, in which a defect is created by removing calcified cartilage and puncturing the 
underlying subchondral bone. Small holes are created for bone marrow components including stem 




it is one of the most common techniques to treat cartilage injuries.(60) Unfortunately, most of these 
clinical approaches are non-ideal and result in undesired complications to the patient.(12, 61) 
Therefore, recent advancements are focused on minimally invasive approaches to facilitate 
cartilage regeneration using various polymeric scaffolds such as Hyalograft© (1999),(62) 
Bioseed© (2001),(63) CaReS® (2006),(64) Atelocollagen gel (2007),(65) Cartipatch® 
(2008),(66) Neocart® (2009),(67) ChondronTM (2010),(68) and Novocart® (2012)(69) to facilitate 
cartilage regeneration. Additionally, Tutobone®, a bovine-origin bone substitute, and Chondro-
Gide® have claimed to aid in osteogenic repair.(70) However, Tutobone® causes xenogenic 
reactions, and due to limited clinical data, this product is not a preferred choice by the 
clinicians.(71)  
 
Most of these approaches involve use of a monolithic structure that fails to mimic the anatomical 
structure or properties. To address this need, various approaches such as multiphasic scaffolds and 
gradient structures have been investigated to mimic the native architecture.(72, 73) For example, 
bilayered scaffolds have been sought as a key design for regeneration of osteochondral tissues. 
Some of the commonly employed bilayered structures can be categorized as “independently 
assembled structures” and “integrated bilayered structures”. In independently assembled 
structures, two discrete scaffolds of bone and cartilage are made individually and then connected 
before or during implantation.(74) On the contrary, integrated bilayered structures are synthesized 
as a composite of two different materials.(54)  
 
Although the aforementioned strategies are promising, they lack the micro- and nanostructural 




determining the healing outcome.(75) To overcome these problems a range of nanomaterials have 
been investigated to mimic the structure and mechanical properties of osteochondral interfaces 
(Table 1). Some of the common nanomaterials that have been exploited for osteochondral interface 
engineering are nanocomposites composed of PCL, poly (L-glycolic acid) (PGA), or PLGA with 
hydroxyapatite or calcium phosphate nanoparticles. In addition, some natural materials have also 
been investigated to mimic the structure of native interface tissue including agarose and 
collagen.(76, 77) In one study, a binary process of extrusion and electrospinning was used to 
fabricate a graded, non-woven network of PCL and tricalcium phosphate nanoparticles (β-
TCP).(46) β-TCP nanoparticles were injected at varying flow rates, which allowed the formation 
of a continuous, linear concentration gradient throughout the electrospun PCL matrix. Mouse 
preosteoblasts were seeded on these scaffolds, and it was observed that the initial rate of cell 
proliferation decreased in comparison to cells seeded on control tissue culture polystyrene.(46) 
This decrease was supported by previously documented results suggesting that the decrease in the 
proliferation was attributed to the onset of differentiation.(78) Four weeks post seeding, a 
considerable amount of calcium deposit, collagen fiber production, and multilayered cells were 









































Graded scaffold mimicking 
structural and compositional 
properties of natural interface 
(46) 
Only bone specific markers were 
explored, the cartilage region of 






Compositional and structural 
gradient created by controlling 
porosity and calcium phosphate 
ion concentration (34) 
Cellular response to graded 






Bilayered scaffold supported 
bone and cartilage regeneration 
in vitro and in vivo, as well as 
exhibited sufficient mechanical 
stability (55) 
Each layer was fabricated 
separately and bone marrow stem 
cells were differentiated on either 





nHAp enhanced hMSC 
proliferation and mechanical 
properties (33) 
Scaffolds were investigated 
individually for bone and cartilage 
regeneration,  not as assembled 






Incorporation of deep zone 
chondrocytes and nHAp 
enhanced collagen production 
and scaffold mechanical 
strength (79) 
Alginate gels did not allow for 
uniform distribution of nHAp (79) 
HA particle size did not 
significantly affect deep zone 






enhancing cartilage anchorage 
to bone ECM  (80) 
Limited characterization of the 






Bilayered scaffolds exhibited 
increased stability and promoted 
bone growth and formation of 
blood vessels (56, 81, 82) 
Trilayered scaffolds 
demonstrated potential for 
promoting cell differentiation 
(83) 
Long-term in vivo stability 





Four layered, gradient scaffold 
exhibited range of mechanical 
properties and initial 
biocompatibility (84) 
Long-term biocompatibility and 








In addition to β-TCP, hydroxyapatite nanoparticles (nHAp) have also been a popular choice for 
osteogenic and osteochondral repair strategies. In another study, collagen scaffolds consisting of 
nHAp crystals were fabricated via a chemical reaction gradient of disodium hydrogen phosphate 
and calcium chloride.(34) This study, however, did not feature any in vitro validation of cellular 
response to this graded scaffold. Alginate and agarose gels combined with nHAp were also 
investigated for osteochondral interface regeneration.(79) The alginate scaffolds did not allow for 
a uniform distribution of hydroxyapatite; whereas, the agarose gels allowed for uniform 
distribution of micro- and nano-sized hydroxyapatite (Figure 1-3a). Both the micro- and nano-
sized hydroxyapatite loaded scaffolds were investigated with interface relevant cells such as deep 
zone chondrocytes (DZC) and hypertrophic chondrocytes induced by thyroid hormone (DZC 
+T3). When the agarose/nHAp composite was seeded with the DZC+T3 cells, there was a 
significant increase in alkaline phosphatase (ALP) activity after 14 days in comparison with the 
control agarose scaffold. Also, on day 14, the addition of nHAp significantly augmented collagen 
X production and Indian Hedgehog (Ihh) expression (Figure 1-3b). The addition of nHAp to the 
agarose gels, resulted in increased compressive modulus (Figure 1-3c). Additionally, there was a 
positive correlation between collagen content and the compressive modulus in the nHAp scaffold 
compared to the microHAp and control scaffolds (Figure 1-3c). However, no significant effect of 
the particle size was observed on the DZC response.(79) In the future, both particle sizes could be 
incorporated into the scaffold since both micro aggregates and nano crystals are found in the native 








Figure 1-3. Nanocomposite scaffolds for osteochondral regeneration. (a) SEM show uniform distribution 
of nHAp in agarose gel and presence of calcium (Ca) and phosphorous (P) is confirmed by EDS and FTIR 
analysis. No significant effect of nHAp on elastic modulus and shear modulus is observed. (b) The effect 
of micro and nano HA particles on GAG and collagen show a significant increase on day 14. Also, the 
addition of particles leads to a significant increase in ALP activity, production of type X collagen and Ihh 
expression on day 14. (c) The cell-loaded scaffolds have significantly higher mechanical stiffness compared 
to the acellular scaffolds. Linear correlation analysis shows a positive relationship between GAG content 
and compressive modulus and shear modulus for all scaffolds. Finally, to determine synergistic affects, a 
significant correlation of GAG + collagen with the nano and micro HA groups is observed. Reproduced 




In another study, an unconventional approach was taken by combining nHAp and polyamide 6 
(nHAp/PA6) with polyvinyl alcohol/gelatin scaffolds to yield a biphasic scaffold.(55) The 
polyamide amalgamation aided in an increased stiffness and mimicked mineral structures of native 
bone tissue, thereby integrating with the osteochondral structure following implantation. A 
common issue associated with most of the autologous implantation protocols is the chondrocyte 




and accrued damage. The group instead acquired bone marrow stem cells, differentiated them in 
vitro into chondrogenic/osteogenic lineage, and seeded them onto the scaffolds. In vivo 
implantation of these biphasic scaffolds yielded regeneration of the osteochondral region. In 
addition, the mechanical and structural properties of the scaffold resembled native cartilage and 
subchondral regions, further warranting its use as an implant material.(55)  
 
Recently, an osteochondral scaffold using agar and poly (ethylene glycol) diacrylate (PEGDA) 
reinforced with nHAp was fabricated.(80) For the bone region, 2% agar loaded with osteoblasts 
was selected and the cartilaginous phase was fabricated from 15% PEGDA and 0.5% nHAp 
(pretreated with growth factors) loaded with mesenchymal stem cells. Finally, a thin stainless-steel 
pin was inserted through the center of scaffold in order to assemble the regions as an osteochondral 
plug. In this study, nHAp was selected to allow for integration between the engineered bone and 
cartilage regions. Also, nHAp aided in stem cell chondrogenic differentiation within the 
cartilaginous region. When tested in vivo, the scaffold integrated well with the host bone tissue 
and demonstrated superior strength, attributed to the addition of hydroxyapatite.(80) In a similar 
approach, nHAp was incorporated in PLGA scaffolds using thermal phase separation.(33) The 
introduction of nHAp to the PLGA scaffold increased the compressive modulus from 400 kPa to 
600 kPa. The efficacy of the nanocomposites was evaluated in vivo using rat models with 
osteochondral defects, by delivering mesenchymal stem cells within the scaffold. After four weeks 
of implantation, the rats showed recovery as highlighted by increased mineralized content, 
collagen production, and hyaline cartilage formation. The study, however, investigated these 




studies on assembled PLGA and PLGA-nHAp should be conducted in order to substantiate these 
findings.(33)  
 
Silk fibroin has also been investigated for various tissue engineering approaches.(56, 81-84, 86, 
87) Specifically for cartilage repair, silk fibroin has been explored because it is a natural material 
which has shown to support cell adhesion as well as only stimulate a low inflammatory 
response.(88, 89) In several studies, silk fibroin and silk-nano calcium phosphate (silk-nCaP) were 
utilized for osteochondral treatment.(56, 81, 82) On study fabricated a bilayered scaffold in which 
a porous silk-nCaP layer was prepared by salt leaching using sodium chloride, and was then 
layered with a porous silk fibroin scaffold (Figure 1-4a,b).(56) SEM and micro-CT were performed 
to characterize the scaffold and confirm the distribution of CaP in the silk matrix (Figure 1-4b-d). 
Although this was a bilayered design, an interface region joined the two distinct layers. The 
osteochondral regeneration potential of the material was evaluated in a rabbit osteochondral defect 
model. The subcutaneous implantation of the scaffold resulted in formation of blood vessels and 
within four-weeks post-implantation, connective tissue was found to adhere to the scaffold surface, 
which support the in vivo biocompatibility of the scaffold. Formation of the interfacial region was 
observed: the silk-nCaP layer induced bone formation and silk promoted type II collagen and 
glycosaminoglycan production (Figure 1-4e). Moreover, the stability of the scaffold addressed the 
problems of long-term in vivo efficacy.(56) In another study, silk fibroin was incorporated into a 
trilayered scaffold for osteochondral tissue regeneration.(83) This 3D scaffold was fabricated via 
a paraffin microsphere leaching process which allowed for control of the pore size and 
interconnectivity. The bone and intermediate layer consisted of silk fibroin and nHAp while the 




stem cells (ADSCs) were seeded onto the bone and cartilage layers of the scaffold and cultured 
separately in osteoinductive or chondroinductive media. In these in vitro microenvironments, 
ADSCs produced bone and cartilage extracellular matrix proteins in the prospective regions. The 
intermediate region remained cell-free and prevented the ADSCs within the bone and cartilage 
regions from mixing with one another. Further studies, specifically in vivo models, need to be 
investigated to observe cellular differentiation capabilities within the scaffold; however, this 
technique provided a promising trilayered scaffold for osteochondral tissue engineering.(83) Silk 
fibroin has also been paired with chitosan and nHAp and in one study, the materials were combined 
to form a four layered porous scaffold in which the top three layers contained a gradient in chitosan 
and silk fibroin and the bottom layer contained chitosan and nHAp.(84) In addition, the scaffold 
contained a gradient in porosity and pore size to represent the natural gradient from calcified layer 
to superficial layer in native articular cartilage. Mechanical properties of the scaffold were assessed 
and an increasing trend in compressive modulus and strength were observed from the first layer 
containing 25wt% chitosan and 75wt% silk fibroin to the bottom layer containing 50wt% chitosan 
and 50wt% nHAp. Finally chondrocytes were seeded on the scaffold to assess biocompatibility, 
and at 14 days cells were viable in all four regions of the scaffold.(84) Although the short-term 
studies proved initial cell adherence and viability, further studies such as investigating extracellular 








Figure 1-4 Bilayered nanocomposite scaffolds for osteochondral regeneration. (a) Synthesis of bilayered 
silk/silk-nCaP scaffold (top) and subsequent implantation in rabbit model (bottom). (b) SEM and EDS 
analysis of the layered scaffold investigates presence of calcium in different zones (Z1-4). (c) CaP 
distribution investigated using micro-CT, showing two distinct layers - silk layer (brown) and composite 
layer (blue). (d) Quantitative analysis of porosity distribution shows homogeneous and interconnected 
porous network in each layer. (e) In vivo studies reveal type II collagen (red) production in the silk layer of 
the scaffold (bottom left), while the control defect does not exhibit any production (top left). Using Safranin 
O, glycosaminoglycan (GAG) formation is present at the edge of the top silk layer (bottom right) but is not 
present in the control defect (top right); the S refers the scaffold and the arrow points to newly formed 




Although the aforementioned scaffolds have shown potential for bone-cartilage regeneration, most 
of them involve addition of cells, which could lead to complications in clinical setting. More 
recently, cell-free scaffolds have gained popularity. These scaffolds stimulate the host environment 




of mechanical and chemical properties of the scaffold.(90) MaioRegenTM (Fin-Ceramica S.p.A., 
Faenza, Italy), a cell-free 3D biomimetic graded scaffold for osteochondral tissue engineering, has 
been investigated in clinical studies.(83, 90, 91) The tri-layered scaffold fundamentally mimics the 
cartilage, interface, and subchondral surface of the bone-cartilage region.(92) It is composed of 
equine-origin type I collagen for the cartilage stimulation, magnesium-enriched nHAp and 
collagen for the intermediate region, and magnesium supplemented with nHAp for the subchondral 
bone regeneration. These layers of the scaffold are deantigenated, preventing any immunogenic 
responses upon engrafting. Furthermore, the scaffold is designed to promote chemotaxis and 
remodeling and the controlled porosity allows for nutrient exchange.(92) These scaffolds are 
usually employed for larger osteochondral defects. Also, the simplicity of the one-step surgical 
procedure involved has been reported to generate favorable outcomes involving minimal follow 
up and complications.(93) However, a recent study reported inconsequential osteochondral 
recovery using this biomimetic scaffold.(90) Additionally, a major ambiguity in these studies is 
the absence of gold standards, therefore, no comparisons are made through controls. More recently, 
another approach for cartilage regeneration was explored using a decellularized cartilage-based 
scaffold.(94) Preliminary results with bone marrow derived mesenchymal stem cells indicated 
increased expression of osteogenic and chondrogenic markers without any external growth factors. 
In the future, this scaffold could be used in an osteochondral defect in vivo and in the complex 
environment regional differentiation may be possible.(94) Although the presented nanomaterial 
approaches for treating bone-cartilage injuries are promising, further studies must be done to 
evaluate these scaffolds as true candidates to replace the clinical standard treatments. In addition, 
many of the approaches only incorporate nanomaterials into the bone region of the scaffold to 




nanomaterials. Future studies could study the effect of incorporating nanomaterials into both 
regions of the scaffold for both structural stability and bioactivity.  
 
1.5 Emerging Trends and Techniques 
A recent surge in the development of new bioactive nanomaterials and our understanding of the 
complex relationships between nanomaterial structure and properties have resulted in the 
expansion of smart and functional biomaterials.(29) The uses of nanomaterials for biomedical 
applications are rapidly expanding and promising new improvements in the area of tissue 
engineering have been demonstrated.(25-27) For example, a range of new bioactive nanomaterials 
such as 2D nanomaterials, metal oxides, and ceramic nanoparticles have been developed to control 
and trigger stem cell differentiation into different lineages (Figure 1-5a). Some of the new 
categories of nanomaterials that have shown promise in the area of orthopedic tissue engineering 
include use of graphene oxides,(43, 44) synthetic silicates,(37, 41) and titanium dioxide 
(TiO2).(45) Due to the exponential growth in nanomaterial development in recent years, it is 
expected to provide a wider selection of nanomaterials with custom physical, chemical, and 
biological characteristics that can be tailored for various biomedical and biotechnological 
applications. Most of these new nanomaterials have not been investigated yet for interface tissue 
engineering and there is tremendous potential to design and develop smart nanomaterials for 
engineering orthopedic tissue interfaces.  
 
A potential avenue for evaluating various nanomaterials for interface tissue engineering is use of 
high-throughput screening (Figure 1-5b). 3D biomaterial microarrays hold enormous promise for 




biomaterials, cells, and the ECM environment for certain applications.(95, 96) The use of 3D 
microarrays can, if optimized correctly, result in more than 1000-fold reduction in biomaterials 
and cells consumption when engineering optimal nanomaterials combinations, which makes these 





Figure 1-5. Emerging trends in interface tissue engineering. (a) Bioactive nanomaterials such as ceramic, 
metal oxides and 2D nanomaterials have potential to control and trigger cellular process. (b) Microarray 
printing technology can be used to screen nanomaterials library in a high-throughput manner. (c) 
Bioprinting techniques can be used to engineering layered scaffold for orthopedic tissue interfaces. (d) The 





In addition, recent efforts on designing functional biomaterials also focus on developing 
multicomponent system consisting of two or more nanomaterials.(26, 27) These multicomponent 




nanoparticles coupled with nHAp and PLLA, have shown to increase osteoblast adhesion and 
proliferation and also provide antimicrobial properties.(97, 98) Although these multicomponent 
nanomaterials have shown increased osteoblast proliferation and promise for bone tissue 
applications, future studies need to be conducted in order for these materials to be applied to 
interface tissue engineering. Additionally, most of these new developed strategies are evaluated 
for bone-related applications and very limited studies focus on evaluating these new nanomaterials 
for other orthopedic tissues including cartilage, tendon, and ligament.(99-101) Thus there is a need 
to investigate these next generation of biomaterials for interface tissue engineering.  
 
Another emerging approach in tissue engineering is additive manufacturing.(102-106) 
Conventional techniques used to fabricate scaffolds for interface tissues include salt leaching, 
electrospinning, phase separation (thermally induced), freeze drying, gas foaming, emulsification, 
and solvent casting and particulate leaching (SCPL). Many of these techniques use salts, porogens, 
and organic solvents, which result in limited cellular infiltration and encapsulation. To overcome 
these limitations, recent approaches have shifted towards additive manufacturing. Some of the 
additive manufacturing approaches that can be used to engineer interface tissues include 3D 
printing,(107-109) stereolithography, air pressure aided deposition,(110, 111) and robotic 
dispensing(112-114). These free-form prototyping techniques face problems of bio-printability, 
which limit the use of printing cells with the scaffolds.  
 
 Recently developed bioprinting techniques can be used to engineer orthopedic tissue interfaces 
(Figure 1-5c). So far, bioprinting has only been used to print one or two types of tissue; however 




gradient tissues.(115) 3D microarray systems can be used to generate layered/gradient-like tissue 
interfaces and such multilayered microgel arrays can be used for high-throughput screening.(95) 
We believe that the development of new high-throughput technologies for studying stem cell 
behavior within multilayered materials would significantly advance the field of interface tissue 
engineering.  
 
Recently, 3D bioprinting can be used to print three different cell types using layer-by-layer 
deposition of custom bioinks (Figure 1-5d). For example, an alginate-collagen bioink revealed that 
cells could be localized in predetermined positions without compromising cell viability.(116) 
Although the cells were not printed with a bioink, this study proves the viability of printing cells 
to control cell placement in a 3D tissue construct. Another aspect of 3D printing that makes it 
appealing for engineering interface tissues is that its resolution would allow for gradients to be 
fabricated not only in the x- and y- directions, but also in the z- direction.(117, 118) In addition, a 
dual nozzle syringe on the printer would make it possible to print multiple biomaterials at the same 
time. Previously, gradients have been fabricated using a gradient maker and mixing chamber in 
which the volume of different materials are controlled and added at different rates to create 
zones.(119) A 3D bioprinter can mimic native tissue architecture with high spatiotemporal control. 
Overall, 3D bioprinting will provide an improved strategy for engineering interface tissues and 
advance the field of tissue engineering.  
 
1.6 Conclusion and Future Directions 
Interface tissue engineering has seen remarkable progress in the past decade with continued 




Nanomaterials such as nanofibrous and nanocomposite scaffolds loaded with hydroxyapatite, 
calcium phosphate, or aragonite are attractive scaffolding materials, since they can control and 
direct cell fate and tune the formation of ECM. Additionally, nanomaterials can be customized to 
control the degradation profile to facilitate tissue regeneration. These nanoengineered scaffolds 
and nanofabrication techniques have the potential to minimize surgical interventions and overcome 
the complexities associated with donor site morbidity. Additionally, nanomaterials can be tuned 
to contain binding sites, growth factors, and signaling proteins, which are important for chemical 
transductions. As new bioactive materials and fabrication technologies are developing, it is 
possible to mimic some of the physical, and chemical properties of native tissues interfaces. 
Specifically, the emergence of bioactive nanomaterials offers promise for directing cell behavior. 
Although, these nanofabricated constructs mimic the interfacial regions efficiently, their clinical 
translation has not been achieved due to lack of strong clinical data. In addition, in order to create 
less invasive surgical procedures to treat injuries at interface tissues, these nanomaterial strategies 
need a minimally invasive delivery method such as an injection. Some nanomaterials strategies 
have emerged that allow for injection and can provide a facile and simple approach for clinical 
applications.(41, 120) However, the effect of shear stress on cell viability and cellular processes 
need detailed investigation using small and large animal models. Another challenge with 
nanomaterials is assessing their short-term and long-term toxicity, especially with the newly 
developed nanomaterials. Long-term accumulation of nanomaterials in body as well as 
inflammatory reaction due to degradation products of nanomaterials need more critical evaluation. 
Overall, nanoengineered scaffolds have become important components in interface tissue 
engineering since they offer an improvement in terms of design and control at the molecular level, 




led to exciting advancements, and there is potential for nanomaterial-based scaffolds to emerge as 
new treatment methods for orthopedic interface tissue injuries. 
 
In the following work, a nanosilicate-platform technology is presented to improve current interface 
tissue or regenerative engineering strategies. Specifically, we investigate nanosilicates, novel two-
dimensional, bioactive nanomaterials which have the potential to replace traditional bioactive cues 
such as growth factors due to their unique biochemical and biophysical properties. We demonstrate 
the innate bioactivity of nanosilicates and their ability to direct human mesenchymal stem cell 
responses including osteogenic and chondrogenic differentiation. We further explore the 
biochemical property of nanosilicates, namely their ionic makeup (Na+0.7[(Mg5.5Li0.3Si8O20(OH)4]
-
0.7) and subsequent dissociation in physiological environments, leading to their innate bioactivity. 
In addition, we utilize the biophysical property, or dual charged surface of nanosilicates to prolong 
and localize delivery of safe, therapeutic concentrations of growth factors to aid in osteogenic and 
chondrogenic differentiation of human mesenchymal stem cells. Finally, we demonstrate 
incorporation of nanosilicates into two natural polymers (gelatin methacrylate and methacrylated 
kappa carrageenan) allows for formation of gradient nanocomposite hydrogels in which cell 
morphology can be controlled. This gradient nanocomposite hydrogel could be used for future 
bone-cartilage interface tissue engineering. Importantly, this work provides a foundation for future 
tissue engineering strategies with the introduction of this nanosilicate-based platform as it can 




2. TWO DIMENSIONAL NANOSILICATES STIMULATE AND MODULATE HUMAN 




2D nanomaterials have gained unprecedented attention due to their unique atomically thin, layered, 
and well-defined structure that provides distinctive physical and chemical properties compared to 
bulk 3D counterparts.(38, 121, 122) As the dimensions of 2D nanomaterials are only a few 
nanometers thick, they interact with biological moieties in a unique way and have raised exciting 
questions about their interactions with cellular components. In addition, different physical (e.g. 
size, shape, and charge) and chemical characteristics of 2D nanoparticles have a multitude of 
effects on cells including toxicity, bioactivity, or therapeutic capabilities, which are not well 
understood.(27, 123)  
 
Understanding cellular responses following treatment with nanomaterials will aid in evaluating 
their application for a range of biomedical and biotechnology applications. Recent emergence in 
“omics” techniques providing readouts of different biological processes, have allowed us to 
understand complex biological interactions of synthetic nanoparticles and their toxicity.(124-127) 
Specifically, transcriptomics and proteomics have laid down the necessary foundation to provide 
                                                 
* Reprinted with permission from “Carrow J.K.; Cross L.M.; Reese R.W.; Jaiswal M.K.; Gregory 
C.A.; Kaunas R.; Singh I.; Gaharwar A.K. Widespread Changes in Transcriptome Profile of 
Human Mesenchymal Stem Cells Induced by Two-Dimensional (2D) Nanosilicates. PNAS, vol. 





an unbiased global view of the cellular activity with pivotal insights about the affected cellular 
pathways. Based on these results, a range of nanotechnology-based platforms have been developed 
for molecular diagnostics and genome-wide analysis.(128) We propose to utilize transcriptomics, 
high throughput sequencing of expressed transcripts (RNA-seq), to provide a holistic view of 
nanomaterial interactions with the cellular machinery. RNA-seq is a powerful tool for an accurate 
quantification of expressed transcripts that largely overcomes limitations and biases of 
microarrays.(129-131) In this study, we will evaluate the potential of bioactive 2D nanomaterials 
for regenerative medicine by uncovering molecular targets and affected signaling pathways at the 
whole transcriptome level.  
 
Synthetic 2D nanoclays have been recently evaluated for regenerative medicine applications, due 
to their biocompatible characteristics, high surface-to-volume ratio, and uniform shape compared 
to other types of 2D nanomaterials.(38, 132-134)  Synthetic clays such as nanosilicates 
(Na+0.7[(Mg5.5Li0.3Si8O20(OH)4]
-
0.7, Laponite XLG®) have disc-shaped morphology and exhibit a 
dual charged surface.(135-137) Nanosilicates dissociate into nontoxic products (Na+, Mg2+, 
Si(OH)4, Li
+) in physiological conditions and show one tenth of the cytotoxicity (LD50~4 
mg/mL)(138, 139) compared to other 2D nanomaterials such as graphene (LD50~100 
g/mL).(140) These 2D nanosilicates are investigated for a range of biomedical applications 
including, tissue engineering, drug and therapeutic delivery, and bioprinting.(141-144) While 
these studies have generated encouraging results for 2D nanosilicates, their interactions affecting 





Here, we investigate the interactions of 2D nanosilicates with hMSCs by employing transcriptome 
dynamics to uncover triggered biophysical and biochemical cellular pathways. In doing so, we 
observed widespread changes in gene expression profile (> 4,000 genes) following nanosilicate 
exposure, which has not been reported previously. In addition, transcriptomic dynamics of 
nanosilicate treated-hMSCs identifies key genes and enriched gene ontology (GO) pathways and 
categories related to stem cell differentiation, specifically towards osteochondral lineages, which 
has not been previously reported. We validated the RNA-seq findings using in vitro studies which 
support the ability of nanosilicates to direct hMSC differentiation towards bone and cartilage 
lineages. Our study also investigated surface-mediated kinase signaling triggered by 2D 
nanosilicates. This work enables further development of nanomaterial-based therapeutics for 
regenerative medicine. More generally, transcriptomic analysis by next-generation sequencing 
provides a comprehensive and objective snapshot of cellular behavior following nanomaterial 
exposure/attachment. Furthermore, this study demonstrates the utility of next generation 
sequencing for the study of cellular interactions on nanoengineered substrates and the role this 
approach is likely to play in this rapidly expanding field of regenerative medicine. 
 
2.2 Materials and Methods 
2.2.1 Nanosilicate Characterization 
Synthetic clay nanosilicates (Laponite XLG®, Na+0.7[(Mg5.5Li0.3Si8O20(OH)4]
-
0.7), was obtained 
BYK Additives (Gonzales, TX). Authentication was performed by determining chemical 
composites, crystal structure, size and shape of nanosilicates. Specifically, inductively coupled 
plasma mass spectrometry (ICP-MS, Elemental Analysis (PerkinElmer NexION 300D) and X-ray 




determine chemical composition of nanosilicates. For ICP-MS, nanosilicates was dissolved in 
0.5% hydrogen peroxide solution for 24 hours. ICP-MS analysis was performed to determine the 
concentrations of Si, Li, and Mg. Dried nanosilicates was used for XPS analysis, where binding 
energies for magnesium (Mg 2s, 2p), sodium (Na 1s), oxygen (O 1s), lithium (Li 1s), and silicon 
(Si 2p) were determined. The raw values were deconvoluted via Lorentzian function using 
GraphPad Prism. X-ray diffraction (XRD, Bruker D8 Advanced) was used to determine crystalline 
structure of nanosilicates. XRD was performed with a copper source on both powdered 
nanosilicates and exfoliated nanosilicates (in water) that were then flash-frozen in liquid nitrogen 
and lyophilized. Atomic force microscopy (AFM, Bruker Dimension Icon Nanoscope) and 
transmission electron microscopy (TEM) was performed to determine the size and shape of the 
nanosilicates. For both AFM and TEM, a dilute solution of exfoliated nanosilicates was placed on 
silicon substrate or carbon grid. For AFM, nanosilicate thickness was observed via tapping mode 
and the data was analysis using Nanoscope Analysis software. For TEM, an accelerating voltage 
of 200 kV using a JEOL-JEM 2010 (Japan) was used to determine the morphology of nanosilicates. 
The zeta potential and hydrodynamic size of nanosilicate-FBS solutions were measured with a 
Zetasizer Nano ZS (Malvern Instrument, U.K.) furnished with a He−Ne laser at 25°C. Filtered 
particles were achieved through utilization of a 0.2 µm filter. 
 
2.2.2 In vitro Studies-Cytocompatibility, Cell Uptake, and Retention 
Human mesenchymal stem cells (hMSCs) were acquired from the Texas A&M Institute for 
Regenerative Medicine (College Station, TX, USA) previously isolated and subsequently 
expanded from voluntary donors under an institutionally approved tissue recovery protocol. 




(alpha-MEM, Hyclone, GE Sciences) with 16.5% fetal bovine serum (Atlanta Biologicals, USA) 
and 1% penicillin/streptomycin (100 U/100 µg/mL, Gibco). After every 2-3 days, half of culture 
media was exchanged for fresh media. Cells were passaged with 0.5% trypsin-EDTA upon 
reaching confluency of ~70% and seeded at ~2500 cells/cm2. All experiments were completed 
with cell populations under P5. Seeded cells were treated with and without nanosilicates (Laponite 
XLG®, Na+0.7[(Mg5.5Li0.3Si8O20(OH)4]
-
0.7) solution (50 µg/mL) and cultured for 7 days.  
 
Metabolic activity was monitored via MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide) (ATCC) and Alamar Blue (Thermo Scientific) assays, per manufacture protocols. The 
BD Accuri C6 Flow Cytometer and a propidium iodide (PI, 40 μg/mL) stain with RNase (100 
μg/mL) were used to perform cell cycle analysis following earlier protocol.(145)  Prior to seeding, 
hMSCs were serum starved (only 1% FBS in media) for 24 hours to synchronize cell populations 
and then treated with nanosilicates. After 48 hours of exposure, cells treated with various 
concentrations of nanosilicates were trypsinized and fixed in ice cold 70% ethanol. Formed cell 
pellets were washed in PBS, followed by incubation in a PI staining solution at 37 °C for 30 
minutes. Cells were stored at 4℃ until flow cytometer analysis. For endocytosis inhibition analysis 
by flow cytometry, cells were cultured under normal conditions in 6-well plates. Cells were 
washed three times with PBS and then treated with inhibitors of clathrin-mediated, calveolar-
mediated, or macropinocytosis (35 μM chlorpromazine hydrochloride, 10 μM nystatin or 400 nM 
wortmannin, respectively) (Sigma–Aldrich) at 37 ˚C for 30 minutes. After this pretreatment, 
silicate nanoparticles fluorescently tagged with Rhodamine B were added to the culture (final 
concentration 100 μg/ml) and incubated for a further 60 minutes. Subsequently, the cells were 




then analyzed via flow cytometry. Hyperspectral images and data were captured using an Olympus 
research grade optical microscope equipped with CytoViva (Auburn, AL) patented enhanced 
darkfield illumination optics and full spectrum aluminum halogen source illumination. The system 
was also equipped with the CytoViva hyperspectral imaging system, producing spectral image 
files from 400nm-1,000nm at 2nm spectral resolution. CytoViva’s customized version of ENVI 
hyperspectral image analysis software was used to quantify the sample’s spectral response and 
conduct any spectral mapping of the sample elements. 
 
For evaluation of reactive oxygen species (ROS) production, the BD Accuri C6 Flow Cytometer 
was used. hMSCs were cultured in a 12 well-plate to ~70% confluency then treated with an ERK 
inhibitor (PD184352, 5 µM) for 2 hours at 37 °C. Cells were then incubated with dihydroethidium 
(DHE, 25 µM) for 10 minutes 37 °C. Then, cells were washed with PBS and treated with 50 µg/mL 
nanosilicates in phenol-red free and serum free media for 2 hours at 37 °C. After 2 hours, cells 
were washed with PBS, trypsinized, spun down, and then re-suspended in PBS for flow cytometer 
analysis. 
 
For lysosomal staining and actin staining, hMSCs were cultured in a 12-well plate to ~70% 
confluency. hMSCs were treated with 1 µL of CellLight® Lysosomes-GFP and incubated 
overnight at 37 °C for lysosomal staining. Then, hMSCs were treated with rhodamine-labelled 
nanosilicates for 3 hours at 37 °C and later fixed with 2.5% glutaraldehyde. Similarly, for actin 
staining, hMSCs were treated with nanosilicates for 24 hours, then fixed with 2.5% glutaraldehyde 
and permeabilized with 0.1% TritonX-100. Phalloidin stain was then added and samples were 




were treated with propidium iodide/RNAase for 30 minutes at 37 °C. Both lysosomal stained and 
actin stained samples were imaged via a confocal microscope (Nikon). Further tracking of 
nanosilicates and lysosomal activity was done using the BD Accuri C6 Flow Cytometer. hMSCs 
were treated with rhodamine-labelled nanosilicates for 1, 3, and 7 days and then treated with 
CellLight® Lysosome-GFP overnight. Cells were then washed with PBS, trypsinized, spun down, 
and resuspended in PBS for analysis.  
 
For investigating nanosilicate dissociation within hMSC culture, inductively coupled plasma mass 
spectrometry (ICP-MS, Elemental Analysis (PerkinElmer NexION 300D)) was performed. 
hMSCs were cultured with nanosilicates for 1, 3, and 7 days and then cells were washed with PBS, 
trypsinized, spun down and then resuspended in deionized water. After re-centrifugation, the pellet 
was digested in a 1% nitric acid, 0.5% hydrogen peroxide solution for ICP-MS analysis in which 
the concentrations of Si, Li, and Mg were determined. This digestion protocol was modified from 
earlier study.(146) 
 
2.2.3 Whole-transcriptome Sequencing and Analysis 
For total mRNA extraction, cells were cultured until 65% confluent and were subjected to two 
different media compositions for one week. One subset of cells maintained normal media 
conditions as a negative control (2 replicates); another group was treated with nanosilicates 
(Laponite XLG®, Na+0.7[(Mg5.5Li0.3Si8O20(OH)4]
-
0.7) (50 µg/mL) for 48 hours (2 replicates), after 
which the media was replaced with normal media for the remaining five days. Excess nanosilicates 
were removed as they are expected to be cleared within 48 hours. Upon completion of the week, 




RNA Isolation kit following the manufacturer’s protocol. Initial quality of nucleic material (~1.5-
2.0 µg) was evaluated using spectrometer absorbance ratios between 280/260 nm around 2.0. 
Samples were analyzed via a high-output HiSeq platform with TruSeqRNA sample preparation 
and single-end read length of 125 bases (Genomics and Bioinformatics Service, Texas A&M 
AgriLife Research, Dr. Charlie Johnson). The sequenced reads were trimmed and aligned to the 
human genome (hg19) using a RNA-seq aligner, Spliced Transcripts Alignment to a Reference 
(STAR).(147) STAR is a RNA-seq alignment algorithm specifically designed for alignment of 
reads generated from spliced RNAs. For the control group, 21,563,695 (uniquely mapped 
20,153,164) and 24,531,989 (uniquely mapped 22,900,448) sequenced reads successfully aligned 
to the genome for the two replicates. Similarly, 22,266,394 (uniquely mapped 20,623,575) and 
15,769,384 (uniquely mapped 14,633,793) reads aligned to the genome for the nanosilicate treated 
group for both the replicates. For further analysis, only uniquely mapping reads were utilized. The 
Reference Sequence (RefSeq) genome annotation the human genome (hg19, GRCh37 Genome 
Reference Consortium Human Reference 37) obtained from UCSC genome browser was utilized 
for obtaining the gene definition. The gene models can also be obtained by using the Bioconductor 
package GenomicFeatures in R environment.(148) Expression of a gene was determined by 
counting the number of uniquely mapped reads overlapping the coding exons normalized by gene 
length in RPKM (reads per kilobase per million). We utilized RPKM to filter the expressed genes 
in the samples and not for comparison between samples. The distribution of expression of genes 
in each sample shows that 1 RPKM is a reasonable cutoff to remove the genes with no or minimal 
expression (Figure S4). Genes >1 RPKM were considered to be expressed in any condition if they 
were expressed in both the replicates. Genes expressed in at least one of the condition were then 




differentially expressed genes where the expression counts were modelled as negative binomial 
distribution.(149)  The bioconductor package DESeq was used for this purpose. Prior to 
performing differential analysis DESeq estimates size factors for each sample for normalizing the 
samples. All analyses were done in R. The GO enrichment analysis was done using GOStats 
bioconductor package. For GO enrichment analysis, the background was only considered to be the 
expressed genes. REVIGO(150) was used to refine the extensive list of significant CC GO-terms. 
It reduces the functional redundancies and clusters the terms based on semantic similarity 
measures. Visualization of gene networks was accomplished through Cytoscape(151)  and 
GeneMANIA(152) and ClueGO(153) by direct comparisons to a Homo sapiens reference genome. 
DAVID Bioinformatics Resources were also utilized for genetic network analysis.(154) Only 
genes with a p adjusted-value (Benjamini-Hochberg false discovery rate) less than 0.05 were 
included within the network and subsequent GO term network formation.  
 
2.2.4 RNA-seq Validation Using qRT-PCR and Western Blot 
For quantitative Reverse Transcription polymerase chain reaction (qRT-PCR), cells were cultured 
under similar conditions as RNA-seq. Following RNA isolation, cDNA was synthesized from 1 
µg of RNA for each sample via SuperScript III Reverse Transcriptase (Thermo Fisher, United 
States) following manufacturer’s protocol. Primers were designed via NCBI/Primer-BLAST and 
quality checked via Integrated DNA Technologies’ OligoAnalyzer. Table 2-1 shows the primers 
designed and used. SYBR Green reagent was then used for amplification quantification. 
Expression and fold change values were calculated from fluorescence using the program DART-
PCR.(155) For Western Blot analysis, cells were cultured under similar conditions as qRT-PCR 




2-mercaptoethanol, 100 mM Tris HCl, and 0.2% bromophenol blue). Gel electrophoresis 
(Invitrogen, Mini Gel Tank) was performed on protein samples and subsequent gels were 
transferred (Invitrogen, iBlot 2) to a nitrocellulose membrane according to manufacture protocol. 
The membranes were blocked with 5% BSA in PBST (PBS + 0.1% Tween 20) for 30 minutes then 
western processed (Invitrogen, iBind). β-actin, COMP, p-MEK1/2, and COL1A1 primary 
antibodies and HRP conjugated secondary antibodies were purchased from Boster Bio and 
incubation was performed per manufacture protocols. Blots were developed (SuperSignalTM 
West Pico PLUS Chemiluminescent Substrate, ThermoFisher) and imaged via LI-COR® 3600 C-
Digit Blot Scanner. Protein bands were quantified with LI-COR software. The blots were then 




Table 2-1. Primer Design for qRT-PCR 
Gene Forward Primer Reverse Primer 
GAPDH 5’-CCTTCATTGACCTCAACTACATGG-3’ 5’-TGGAAGATGGTGATGGGATTTCC-3’ 
COMP 5’-AACAGTGCCCAGGAGGAC-3’ 5’-TTGTCTACCACCTTGTCTGC-3’ 
ACAN 5’-AAGGGCGAGTGGAATGATGT-3’ 5’-CGTTTGTAGGTGGTGGCTGTG-3’ 
CLTCL1 5’-TTTTGGCAGGTCAGGCATCC-3’ 5’-ACCTGTGCTTTCCCAAGACT-3’ 
COL11A1 5’-GACTATCCCCTCTTCAGAACTGTTAAC-3’ 5’-CTTCTATCAAGTGGTTTCGTGGTTT-3’ 




2.2.5 In vitro Functional Study 
For differentiation studies, hMSCs were treated with either osteogenic (normal media 




(DMEM supplemented with 1% ITS+, 10-7M dexamethasone, and 1 mM sodium pyruvate) with 
and without nanosilicates. For osteogenic differentiation samples were fixed with 2.5% 
glutaraldehyde at 14 and 21 days and stained for alkaline phosphatase (1-Step NBT (nitro-blue 
tetrazolium chloride)/BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt) substrate 
solution, ThermoFisher Scientific) and mineralization (Alizarin Red S stain, Electron Microscopy 
Sciences), respectively. Alizarin Red was quantified via acetic acid extraction and subsequent 
colorimetric detection.(156) For chondrogenic differentiation, samples were fixed with 2.5% 
glutaraldehyde at various time points, washed with PBS, 1% acetic acid, and then quickly stained 
with 0.1% Safranin O for 5 minutes. Samples were washed again with PBS twice and then imaged. 
For immunostaining, fixed cells were incubated with a 1% BSA in PBST (PBS + 0.1% Tween 20) 
for 30 minutes to block nonspecific binding. Cells were then incubated with a mouse anti-human 
aggrecan primary antibody (Abcam, MA, USA) within a 1% BSA solution overnight at 4°C. The 
primary antibody was then removed and cells were washed with PBS multiple times. 
Subsequently, cells were incubated for 1 hour at room temperature with a goat anti-mouse IgG 
with conjugated Alexa Fluor® 647 (Abcam, MA, USA) in a 1% BSA solution. The secondary 
antibody was then decanted and cells were washed multiple times with PBS. Samples were stored 
in PBS in the dark at 4°C until imaging. 
 
2.2.6 Statistical Analysis 
Statistical analysis was performed via GraphPad Prism software. One-way ANOVA with post 
hoc Tuckey tests were performed. Significant significance values were determined as P values 





2.3 Results and Discussion 
2.3.1 Biophysical and Biochemical Characterization of Nanosilicates 
Chemical and structural characteristics of 2D nanomaterials will dictate their interactions with 
cells.(27) A range of material characterization techniques were used to establish the chemical 
composition, crystalline nature, shape, and size of nanomaterials.(157) Transmission electron 
microscopy (TEM) showed that nanosilicates were 20-50 nm in diameter (Figure 2-1a). X-ray 
photoelectron spectroscopy (XPS) revealed the presence of oxygen (54.68%), silicon (28.99%), 
magnesium (15.27%), sodium (0.84%), and lithium (trace), which is similar to expected 
stoichiometry (Na+0.7[(Mg5.5Li0.3Si8O20(OH)4]
-
0.7) (Figure 2-1b). The thickness of nanosilicates 
was determined to be around 1-2 nm using atomic force microscopy (AFM) (Figure 2-1c). The 
crystalline structure of nanosilicates was corroborated by observing characteristics diffraction plan 
(001), (100), (005), (110), (200), and (300) using x-ray diffraction (XRD) (Figure 2-1d). After 
exfoliation, a decrease in 2θ (20.1 to 16.8) for diffraction plane (100), indicates an increase in d-








Figure 2-1 Physical characterization of nanosilicates was completed to evaluate particles before 
introducing to hMSCs. (A) TEM of nanosilicates demonstrated disk morphology and nanoscale size. (B) 
XPS analysis revealed an elemental composition similar to that of the idealized stoichiometric ratio found 
within a unit cell of the nanosilicates. (C) AFM corroborated the nanoscale diameter (25-50 nm) and 
thickness (1-1.5 nm) of the nanosilicate. (D) XRD of both bulk and exfoliated (flash frozen with subsequent 
lyophilization) nanosilicates generated peaks at diffraction planes (001), (100), and (005) for both, with 
(110) and (300) present in bulk sample. (E) DLS measurements quantified variability of nanosilicates 
hydrodynamic size in particles and displayed a narrow range of diameters (polydispersity index, 0.22) 




In biological media, such as blood plasma, synovial fluid or even culture media, the surface of 
nanoparticles become coated with various biomolecules forming a protein corona. Oftentimes, this 
initiates internalization of nanoparticles via receptor-mediated endocytosis. The binding of 
proteins to the nanosilicate surface was evaluated by monitoring hydrodynamic diameter (DH) and 




potential of the nanoparticles shifted from -40 mV to -25 mV, indicating that the negatively 
charged surface of the nanosilicates was coated with biomolecules. Similarly, an increase in 
hydrodynamic diameter was observed from ~45 nm to ~90 nm after placement in biological media. 
These results indicated that nanosilicate surfaces strongly interacted with biomolecules via 
electrostatic interactions to result in physical adsorption thereby enhancing interactions at the 
nano-bio interface.  
 
The effect of nanosilicates on cell health was evaluated by monitoring cytoskeletal organization, 
metabolic activity and cell cycle (Figure 2-2). An investigation into cell health via metabolic and 
viability assays (Alamar Blue and MTT) confirmed cytocompatibility of nanosilicates until the 
concentration of nanosilicates reached 100 µg/mL. In addition, hMSCs treated with nanosilicates 
showed similar cytoskeletal organization to untreated hMSCs. Cell cycle analysis also supported 
that the majority of cells were in G1 and G2 phases when treated with <100 µg/mL nanosilicates. 








Figure 2-2 Nanosilicates effect on cellular processes. (A) Metabolic activity, assessed via MTT assay, 
remained unaffected by nanosilicate introduction at bioactive concentrations. Minimal effect of 
nanosilicates was observed on cell health monitored via (B) Alamar blue assay, (C) cytoskeletal 




2.3.2 Receptor-Mediated Endocytosis of Nanosilicates 
The absorbed proteins on the nanomaterial surface are predicted to influence cell surface receptor-
mediated cellular uptake (Figure 2-3a). We used hyperspectral imaging(158) to visualize 
internalized nanosilicates (Figure 2-3b) without requiring chemical modifications that could have 
impacted uptake dynamics. Flow cytometry also demonstrated uptake of fluorescently labeled 
nanosilicates in a concentration-dependent manner (Figure 2-3c and Figure 2-4a, R2 = 0.996).  
 
The mechanism behind nanosilicate (50 µg/mL) internalization was evaluated using chemical 
inhibitors to block specific endocytic pathways. We observed a significant decrease in cellular 




hydrochloride) (Figure 2-3d). Alternatively, other endocytic mechanisms such as caveolar-
mediated (nystatin) and micropinocytosis (wortmannin) played a less prominent role in 
nanosilicate uptake. Furthermore, nanosilicate binding to the cell membrane and subsequent rapid 
internalization within 5 min (Figure 2-4b) are consistent with clathrin vesicle dynamics.(159) 
Colocalization of nanosilicates near or within lysosomal vesicles further confirmed nanosilicate 
trafficking (Figure 2-3d). These results indicated that nanosilicates are readily internalized by cells 








Figure 2-3 Biophysical interaction of nanosilicates and hMSCs. (A) Two-dimensional nanosilicates 
electrostatically bind to proteins from biological fluids and are subsequently internalized by cells via 
surface-mediated endocytosis. (B) Hyperspectral imaging indicating distribution of nanosilicates 
throughout the cell body following endocytosis. The image was captured from transverse section of cell 
body. (C) Flow cytometry analysis of rhodamine-tagged nanosilicates demonstrate dose-dependent cellular 
uptake. The nanosilicates were primarily internalized via clathrin-mediated process (chlorpromazine) as 
opposed to micropinocytosis (wortmannin) or caveolar-mediated (nystatin). **P-value < 0.01; ***P-value 
< 0.001. (D) LAMP1 staining (green) for lysosomal membranes further tracks nanosilicates (red) following 
endocytosis. (F) Row-scaled z-scores of quantile normalized gene expression [in log2(RPKM)] of 
>4000genes following treatment with nanosilicates (padjust < 0.5, red, up-regulated: 1,897 genes; blue, 
down-regulated: 2,171 genes). (G) Significant gene ontology (GO) terms of associated biological processes, 
cellular components, and molecular functions from differentially regulated genes (P < 0.5). Terms related 
to biological process and cellular components indicate strong biophysical interactions between cells and 
nanosilicates. (E) Clustering of significant 244 cellular component GO terms into broader cellular 
component categories. (H) Gene network displaying interconnected genetic targets after nanosilicate 
treatment with high degrees of expression and statistical significance (red, up-regulated; blue, down-















Following uptake, nanosilicates remained within the cell for more than 7 days and were not 
exocytosed or dissociated immediately. The retention of nanosilicates by cells was determined 
using flow cytometry. A steady decrease was observed over a course of 7 days in cells staining 
positive for nanosilicates, that is, day 1 (96.3 ± 4.8%), day 3 (69.0 ± 10.6%), and day 7 (32.8 ± 
19.5%) (Figure 2-4c). To further confirm this, we monitored nanosilicate retention by cells over a 
week with inductively coupled plasma mass spectrometry (ICP-MS) (Figure 2-4d). The 
nanosilicate content was decreased by 31% on day 7, compared with day 1. Over the course of 7 
days, cells also maintained an enhanced lysosomal vesicle response (Figure 2-4c). The stability of 
nanosilicates in physiological microenvironment was evaluated at pH 7.4 (mimicking cell body) 




release of minerals at pH 5.5 was observed compared with 7.4, indicated the predicted in vitro 
dissociation of nanosilicates. After 7 days, release of silicon (~10%), magnesium (~6%), and 
lithium (~16%) was observed at pH 5.5. These results indicate that nanosilicates were retained by 





Figure 2-4 Nanosilicates interactions with hMSCs were monitored using flow cytometry and ICP-MS. (A) 
Uptake of fluorescently tagged nanosilicates displayed concentration-dependent internalization. (B) 
Endocytosis of particles occurred rapidly with chemical inhibition of a clathrin-mediated process reducing 
uptake. (C) Following internalization, tagged particles were trafficked to lysosomal bodies with an increase 
in these vesicles observed after 24 hours and returning to basal levels over the course of a week. (D) 
Introduction of nanosilicates to low-pH environments of late endosome/lysosome vesicles initiated 
dissolution of the particles over a week. Ion products were greatest at 24 hours and decreased over time as 







Dissolution of nanosilicates inside cells can trigger biochemical signaling via release of minerals 
in cytosol. Earlier studies have shown that mineral ions can significantly influence cell functions. 
For example, silicon ions have been shown to direct stem cell differentiation by triggering cWnt 
signaling pathways and are critical for cartilage development.(160, 161) Likewise, magnesium 
ions have been shown to up-regulate production of COL10A1 and VEGF in hMSCs.(162) Lithium, 
an inhibitor of glycogen synthetase kinase-3β (GSK-3β), activates Wnt-responsive genes by 
elevating cytoplasmic β-catenin.(163, 164) These studies suggest that intracellular release of ionic 
dissolution products of nanosilicates (Si(OH)4, Mg
2+, Li+,) could stimulate hMSC differentiation.  
 
2.3.3 Widespread Transcriptomic Changes Triggered by Nanosilicates 
Sequencing of expressed mRNAs by RNA-Seq can be used to determine genome-wide changes in 
gene expression resulting from cellular response to external stimuli.(165) hMSCs (2,500 cells per 
cm2) were exposed to nanosilicates (50 µg/mL), and whole-transcriptome sequencing (RNA-seq) 
was performed after 7 days. (Materials and Methods). The 7-day time point was chosen to provide 
a broad overview of cell processes, ranging from endocytosis and proliferation to early 
differentiation. Two replicates of untreated and treated hMSCs were sequenced. The sequenced 
reads were aligned to reference genome (hg19) using RNA-seq aligner. The normalized gene 
expression levels were determined by calculating reads per kilobase of transcript per million 
(RPKM) (Figure A-1a,b). The replicates for both the conditions showed high concordance (r = 
0.99, Figure A-1c). We used generalized linear models (GLMs) to identify differential gene 
expression (DGE) between nanosilicate treated hMSCs and untreated hMSCs (Materials and 




(Figure 2-3e; 1,897 up-regulated genes, 2,171 down-regulated genes, false discovery rate-adjusted 
P < 0.5). Such widespread changes in gene expression profile have not been reported earlier. For 
example, human dermal fibroblast cells treated with gold nanoparticles were shown to 
differentially regulate 1,439 genes,(166) while another study demonstrated that human immune 
cells treated with graphene oxide experienced differential regulation of 1,147 genes.(167) It is 
important to note that these previously reported studies were performed using microarrays (166, 
167) and the widespread effect of nanoparticles on whole transcriptome was not investigated. 
Thus, our result strongly suggests that nanoparticle treatment leads to a widespread cellular 
response that is reflected by the change in transcriptome profile of hMSCs treated with 
nanosilicates, requiring further exploration into prominent cellular pathways.  
 
DGE following nanosilicate introduction spanned a host of cellular processes and functions. To 
identify the key biological processes and pathways that are affected when the cells interact with 
nanosilicates, we performed GO enrichment analysis of the three GO categories [biological 
processes (BP), cellular components (CC), and molecular functions (MF)]. Nanosilicate treatment 
showed significant enrichment for 1,132 GO terms (P < 0.05), including 884 for BP, 134 for CC, 
and 114 for MF (Figure A-1d). We then narrowed down key GO terms based on high significance 
(P value) in each category to highlight the widespread effect of nanosilicates on hMSCs (Figure 
2-3f). The key GO terms significantly enriched in BP were endocytosis (GO: 0006897) and 
endochondral growth (GO: 0003416). The analysis also indicated positive regulation of mitogen-
activated protein kinase (MAPK) cascade (GO:0043410), transforming growth factor-β (TGF-β) 
receptor signaling pathway (GO:0007179), notch signaling pathway (GO:0007219), canonical 




signaling (GO:0030509). GO analysis also supported our observation that nanosilicates are 
internalized via clathrin-mediated endocytosis (GO:0072583). Overall, the GO enrichment 
analysis indicated that the predominant downstream effect of nanosilicates was on kinase activity, 
cell differentiation, and extracellular matrix (ECM) reorganization. 
 
Functional annotation clustering performed using Database for Annotation Visualization and 
Integrated Discovery (DAVID)(168) highlights the role of cell membrane-mediated signaling due 
to nanosilicate treatment. We then use REVIGO(169) to refine the extensive list of significant CC 
GO terms by reducing functional redundancies and clustering the terms based on semantic 
similarity measures. GO for CC was enriched for cytosolic, ribosome, focal adhesion, and 
endosomal processes (Figure 2-3g and Figure A-1e). These results further suggested a sequence 
of events initiated at the cell membrane through protein localization to membrane (GO:0072657) 
and endocytic vesicle formation (GO:0006897, GO:0006898) accompanied by protein targeting to 
membrane (GO:0006612), and trafficking by lysosome (GO:0043202, GO:0005764). Specifically, 
genes involved in clathrin-mediated endocytosis (GO:0072583) like CLTCL1, which encodes a 
major protein of the polyhedral pit and vesicle coat, were significantly affected. To validate the 
clathrin-mediated endocytosis, change in expression level of CLTCL1 was confirmed using 
quantitative reverse transcription-PCR (qRT-PCR) (Figure A-1f). We then clustered differentially 
expressed genes (P < 0.5) using Cytoscape(170) into different cellular processes such as basic cell 
processes, kinase signaling, endocytosis, and stemness/regenerative capacity (Materials and 
Methods). Networks between genes from same pathways were generated to illustrate connected 




Overall, these results demonstrate that nanosilicates significantly affect the transcriptomic profile 
of hMSCs, which can translate to measurable changes in behavior. 
 
2.3.4 Nanosilicates Activate Surface-Mediated Signaling 
The high surface-to-volume ratio and dual charged surface of nanosilicates are expected to 
facilitate strong interactions with the cell membrane. The physical interactions between cells and 
nanoparticles are expected to stimulate a variety of intracellular signaling events including 
proliferation and differentiation.(27, 171, 172) Accordingly, a significant change in expression of 
upstream regulators of Ras (e.g., RalB, DDIT4, and HRAS) and Rho (e.g., DMPK, PAK2, and 
ECT2) subfamilies of GTPases was observed upon nanosilicate treatment. These Ras and Rho 
genes are associated with peptidyl-serine phosphorylation (GO:0033135) and protein 
serine/threonine kinase activity (GO:0071900). Both Ras and Rho GTPase subfamilies affect cell 
behaviors such as cytoskeletal arrangement, cell migration, and stem cell fate.(173, 174) From 
analyzing enriched GO pathways related to stress, two prominent membrane-activated cascades 
emerged: the MAPK cascade and Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) pathway (Figure 2-5a). Genetic markers specific to extracellular signal-regulated 
kinases (ERKs) ERK1/ERK2 regulation (GO:0070374, GO:0071363), stress-activated MAPK 
(GO:0032872, GO:0031098) cascades, and JAK/STAT cascade (GO:0007259) were also 
significantly altered following nanosilicate treatment. Among these enriched GO terms, multiple 
genes displayed notable log2fold changes in expression such as IGFBP2 (insulin-like growth 
factor binding protein 2) (log2fold: 1.358), IGFBP3 (1.149), TAOK1 (-1.864), PDGFRA (-1.394), 
and HIPK2 (-1.237). A significant change in gene expression of key MAPK signaling regulators 





We also observed that a large number of genes (76 out of 170 genes) related to stress-activated 
protein kinase signaling (GO:0031098) were differentially expressed due to nanosilicate treatment 
(Figure 2-5b). Specifically, TAOK1, TXNIP, and MAP4K4 exhibited a distinct difference in 
expression between nanosilicate-treated hMSCs compared with control hMSCs (Figure 2-5c and 
Figure A-3c). TAOK1 is an activator or the p38/MAPK14 stress-activated cascade.(175) The 
change in mRNA expression levels of TAOK1 via RNA-seq was further validated using qRT-PCR 
(Figure 2-5d). These data strongly support the ability of nanosilicates to stimulate MAPK cascade, 
specifically that of the ERK and p38 pathways (Figure 2-5e). 
 
To experimentally validate the cross talk between MAPK signaling pathways following 
nanosilicate treatment, flow-cytometric analysis was performed. Reactive oxygen species (ROS) 
produced by cells treated with and without nanosilicates in presence of ERK inhibitor [PD184352, 
mitogen-activated protein kinase 1/2 (MEK1/2) inhibitor] were monitored using ROS-sensitive 
reporter fluorophore (Figure 2-5f). ROS play a role in the ERK pathway via cross talk from 
mitogen-activated protein kinase kinase kinases.(176) For nanosilicate-treated hMSCs, a 
significant reduction in ROS production was observed due to the presence of ERK inhibitor as 
seen by reduced fluorescence signal (~32% reduction, P < 0.05). This reduction in ROS production 
via the ERK inhibitor indicates the stimulation of MAPK signaling, specifically that of ERK, by 
the nanosilicates. The mechanism of this activation may stem from the biophysical cell-
nanoparticle interaction, biochemical dissolution, or both in conjunction. This study validates that 
hMSCs recognize and respond to nanosilicates by engaging intracellular programs such as MAPK 








Figure 2-5 Nanosilicates lead to stress-induced MAPK signaling. (A) Nanosilicate treatment results in 
activation of stress-related response. A list of significant GO terms related to stress after nanosilicate 
treatment indicate signal propagation via MAPK/ERK signaling pathways. (B) The majority of genes 
involved in stress-activated kinase signaling cascade (GO:0031098) undergo a significant differential 
expression. (C) The change in gene expression profile of MAP4K4 and TAOK1 (aligned reads normalized 
by total library size). (D) Comparison of TAOK1 gene expression obtained from RNA-seq was validated 
using qRT-PCR. (E) Nanosilicates trigger a stress-responsive kinase cascade (Ras-Raf-MEK-ERK 
pathways), leading to changes in reactive oxygen species (ROS) production and subsequent RNA 
transcription and protein synthesis. (F) Flow-cytometric analysis was performed to measure the stress-
responsive kinase cascade, by measuring ROS production with ROS-sensitive fluorescent reporter dye. 
Experiments were performed in the presence or absence of a MAPK inhibitor. A significant increase in 
ROS-mediated fluorescent signal is observed upon exposure to nanosilicates, and this is abrogated after 
treatment with the MAPK inhibitor. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (G) Production 
of p-MEK1/2 was determined using Western blot in presence of nanosilicates and MEK inhibitor, 












While RNA-seq analysis provided insight about the role of nanosilicates in stimulating MAPK-
related pathways, including those typically stimulated by growth factors in addition to stress-
responsive kinases, monitoring protein levels can further provide functional evidence. Differential 
expression was observed in both upstream (e.g., RAS, PRKCA, and BRAF) and downstream (e.g., 
ELK1, MKNK2) genes of MEK1/2. In the MAPK/ERK cascade, MEK1 and MEK2 control cell 
growth and differentiation.(177) Activation of MEK1 and MEK2 occurs through phosphorylation 
by Raf. MEK1.2 inhibitors have been used extensively to implicate ERK1/2 in a wide array of 
biological events. To validate MAPK/ERK pathways, we monitored synthesis and 
phosphorylation of MEK1/2 (p-MEK1/2) with and without a MEK1/2 inhibitor (Figure 2-5g) via 
Western blot. hMSCs had relatively low production of p-MEK1/2, while nanosilicate treatment 
results in more than six-fold increase in p-MEK1/2. In the presence of MEK1/2 inhibitor, 
production of p-MEK1/2 in the presence of nanosilicates was suppressed, demonstrating the role 





Beyond intracellular phosphorylation events within MAPK cascades, we also observed genes that 
play a role in controlling background processes of hMSCs, like multipotency and motility, that 
have been identified in literature.(178) RNA-seq analysis revealed a significant change in gene 
expression: AFAP1 (log2foldΔ: -1.152), SOCS5 (-1.192), WNT5A (-1.162), INHBA (-1.179) from 
a variety of pathways including TGF-β, JAK/STAT, Wnt/ β -catenin, and phosphatidylinositol-3-
kinase (PI3K) signaling. As this subset of genes is involved in cell proliferation, stromal cell 
multipotency, and extracellular matrix production,(179-181) nanosilicates may therefore improve 
functional tissue regeneration. Therefore, we were prompted to investigate these downstream 
pathways using molecular analysis techniques. 
 
2.3.5 Nanosilicates Direct Stem Cell Differentiation 
Following nanosilicate treatment, activation of the membrane can lead to differentiation and 
extracellular matrix deposition, following an ERK-based cascade. The kinase signaling follows 
similar progressions in hMSCs after growth factor simulation to promote osteochondral 
differentiation.(182-186) Evidence of hMSC inclination toward bone and cartilage lineages 
following nanosilicate treatment was observed with GO term enrichment (Figure 2-6a and Figure 
A-4). GO pathways and biological processes related to osteogenesis, such as bone development 
(GO:0060348), endochondral bone growth (GO:0003416), biomineral tissue development 
(GO:0031214), and canonical Wnt signaling pathway (GO:0060070) were favored toward 
osteogenesis. For chondrogenesis, cellular response to transforming growth factor-β stimulus 
(GO:0071560), cartilage development involved in endochondral bone morphogenesis 
(GO:0060351), and hyaluronan metabolic process (GO:0030212) were significantly altered. We 




example, 49 out of 92 genes were differentially expressed for bone development (GO:0060348), 
while 10 out of 14 genes were differentially expressed for cartilage development (GO:0060351) 
(Figure 2-6b). Genes from these GO categories including cartilage oligomeric matrix protein 
(COMP), collagen type I α1 chain (COL1A1), collagen type XI α1 chain (COL11A1), and aggrecan 
(ACAN), were significantly up-regulated due to nanosilicate treatment (Figure 2-6c and Figure A-
5a) We further validated these genes using qRT-PCR and observed comparable gene expression 





Figure 2-6 Transcriptomic analysis elucidates nanosilicate-induced bioactivity. (A) GO terms related to 
osteogenesis and chondrogenesis indicate nanosilicate-induced hMSC differentiation. (B) Significant gene 
expression changes in genes involved in bone development (GO:0060348) and cartilage development 
(GO:0060351). (C) Gene expression profile of COMP, COL11A1, and ACAN, demonstrating up-regulation 
due to nanosilicate treatment (aligned reads normalized by library size). (D) Differential gene expression 












To ensure that the mRNA detected represented up-regulated protein levels, a Western blot for 
COMP and COL1A1 was performed on day 7. Both COMP and COL1A1 protein showed a 
significant increase in expression due to nanosilicate treatment, indicating their role in hMSC 
differentiation (Figure 2-7a). Based on the changes in transcriptomic profile and in vitro validation, 
we hypothesize that the activation of MAPK/ERK pathways by nanosilicates may lead to 
differentiation into osteochondral lineages. To confirm the role of nanosilicates in stimulating 
MAPK/ERK signaling for hMSC differentiation, a MEK1/2 inhibitor was utilized and resulted in 
a significant decrease in COMP protein synthesis (Figure A-5b). This indicated the role of 
nanosilicates in the activation of MAPK/ERK signaling to direct the differentiation of hMSCs. 
 
Finally, to further substantiate the ability of nanosilicates to drive hMSC differentiation toward 
bone and cartilage lineages, staining of lineage-specific proteins and matrix mineralization was 
performed. The effect of nanosilicates on chondrogenic and osteogenic differentiation was 




osteo-conductive (lacking bone morphogenetic protein 2 (BMP2) or dexamethasone) media. After 
21 days, production of chondro- and osteo-related ECM was observed even in the absence of 
inductive supplements. An increase in both glycosaminoglycan (GAGs) and aggrecan production 
were observed in nanosilicate-treated hMSCs indicating chondrogenic differentiation (Figure 2-
7b), while for osteogenic differentiation, an increase in alkaline phosphatase (ALP) production as 
well as matrix mineralization (calcium phosphate) were observed (Figure 2-7c). These results 
validated the ability of nanosilicates to induce hMSC differentiation into bone and cartilage 





Figure 2-7 Nanosilicate-induced hMSC differentiation. (A) Western blot showing production of COL1A1 
and COMP after exposure to nanosilicates for 7 days in normal media. (B) The effect of nanosilicates on 
production of GAGs was determined by safranin O and aggrecan staining after culturing hMSCs in 
chondro-conductive media for 21 days. (C) The effect of nanosilicates on osteogenic differentiation was 
determined by ALP activity and formation of mineralized matrix after culturing hMSCs in osteo-conductive 







The broader relevance of our study is that “omics” techniques can be used to determine the effect 
of nanomaterials on cells in a nontargeted and nonbiased approach. The physiochemical properties 
of engineered nanomaterials such as size, shape, surface charge, and chemical composition will 
have profound effects on cellular behavior.(27, 171) Therefore, we do not speculate that the 
transcriptomic changes observed in this study will be universal to all types of nanomaterials or 
even single-cell analyses. Recent studies have used bulk population “omics” approaches to 
understand nanotoxicology and mechanism-based risk assessment of nanomaterials.(187, 188) 
The current study demonstrates the capabilities of next generation sequencing to monitor mRNA 
expression levels in the cell after nanomaterial treatment. Our approach overcomes the limitation 
of measuring expression levels of preselected genes on microarrays, which can therefore identify 
previously neglected cellular signaling pathways relevant for regeneration. Additionally, RNA-
seq delivers a low background signal and sequenced reads that can be unambiguously mapped to 
unique regions of the genome, which will help in sensitive and precise identification of the 
expressed genes. The transcriptomic insight on the role of surface-mediated cellular signaling 
supports the ability of nanosilicates to induce hMSC differentiation into bone and cartilage linages 
in the absence of inductive agents. This insight can assist in reducing or eliminating the use of 
supraphysiological doses of growth factors currently employed in clinical practice for regenerative 
therapies. These omics techniques can likewise reveal cell-material interactions unique to specific 






2.4 Conclusion  
Overall, we investigated a transcriptomic snapshot of hMSCs in which a widespread change in 
transcriptomic profile was observed in response to nanosilicate exposure. The transcriptomic 
changes observed due to nanosilicate treatment likely originate from both biophysical and 
biochemical mechanisms. The interaction of nanosilicates with the cell membrane stimulated 
various surface receptors, including the stress-responsive and surface receptor-mediated MAPK 
pathways. Similarly, the data indicate that internalization of nanosilicates and subsequent release 
of mineral ions trigger biochemical signaling that could promote osteochondral differentiation of 
hMSCs. Accordingly, analysis of the transcriptomic snapshot of hMSCs treated with nanosilicates 
uncovered families of genes related to osteochondral differentiation. In vitro studies validated the 
RNA-seq findings and further supported the observation that nanosilicates have the capacity to 
direct hMSC differentiation toward bone and cartilage lineages. Last, RNA-seq emerged as a 





3. MINERAL NANOPARTICLE DISSOCIATION INFLUENCES HUMAN 




Traditional regenerative medicine strategies adhere to the tissue engineering paradigm in which 
cells and bioactive cues are incorporated into a scaffold to mimic native tissue.(189, 190) While 
this approach has been successful, recently, the use of conventional bioactive cues, specifically 
growth factors, has become unfavorable. Once growth factors are delivered to the physiological 
space, they are volatile and susceptible to rapid degradation.(191, 192) As a result, clinicians must 
use large or supraphysiological doses of growth factors, 100-1000-fold higher compared to 
physiological concentrations, to maintain therapeutic efficacy. However, the use of the high doses 
has then led to several negative side effects including inflammation and uncontrolled tissue 
growth.(193-196) Due to the rise in these complications, researchers are investigating strategies to 
reduce and potentially replace these traditional bioactive proteins while maintaining cellular 
modulation capabilities. 
 
One such alternative, specifically mineral-based nanoparticles, has gained interest in regenerative 
engineering. The mineral composition of these particles can be tailored toward specific 
regenerative applications through the release or dissolution of unique ionic products, which can 
directly stimulate cellular processes.(197) As a result, these mineral-based particles have the 
potential to replace conventional bioactive cues. An emergent mineral-based nanomaterial, termed 
nanosilicates (Na+0.7[(Mg5.5Li0.3)Si8O20(OH)4]




variety of biomedical applications, including regenerative engineering.(141, 198, 199) 
Nanosilicates have not only demonstrated high cytocompatibility with human mesenchymal stem 
cells (hMSCs), but also innate bioactivity.(32, 200, 201) Specifically, a recent study using RNA-
sequencing of hMSCs after exposure to nanosilicates, revealed upregulation of osteogenic and 
chondrogenic differentiation in the absence of growth factors.(201) While these studies have 
produced encouraging results for nanosilicate innate bioactivity, the use of nanosilicates as an 
alternative bioactive cue to replace or augment growth factors remains elusive due to the undefined 
mechanism of action.  
 
Previous investigation into nanosilicate-cell interaction has shown these particles to be internalized 
via clathrin mediated endocytosis.(139, 201) In addition, previous studies have shown nanosilicate 
dissolution or dissociation into Li+, Mg2+, and Si(OH)4 at pH below ~9 and the extracellular and 
intracellular physiological pH of 7.4 and 5.5, respectively, facilitate this dissociation.(136, 202) 
We believe the genetic changes observed in the previous RNA-seq study could result from the 
chemical makeup of the nanosilicates and subsequent ion dissociation following particle uptake. 
Some earlier studies have investigated specific ions individually and demonstrated their potential 
to stimulate pathways related to osteogenic differentiation. For example, Li+ inhibits glycogen 
synthetase kinas-3β (GSK-3β) which activates Wnt-responsive genes elevating cytosolic β-
catenin.(163, 164, 203) Both ex vivo and in vivo studies have demonstrated Li+ to initiate Wnt 
signaling which in turn stimulates osteogenesis.(163) In addition, Si(OH)4 promotes collagen type 
I synthesis and osteoblast differentiation via Wnt/B-catenin signaling.(160, 161) Finally, Mg2+ has 
been deposited onto biomaterial surfaces to improve cell adhesion since divalent cations affect 




extracellular environment and cells and control cellular processes such as proliferation and 
differentiation.(204-206) While these previous studies have demonstrated the potential for 
individual ions to induce osteogenic differentiation, the inclusion into a single nanoparticle allows 
for intracellular delivery and local release of the ions. We aim to investigate the effect of individual 
ions dissociated from the nanosilicates on osteogenic differentiation of hMSCs. 
 
In this study, we investigate a potential underlying causation of nanosilicate-induced osteogenic 
differentiation, specifically, the effect of the individual ions contained in nanosilicates. We 
examine nanosilicate dissociation at physiological pH, as well as the role of these individual 
degradation products (lithium, magnesium, and silicon) in osteogenic differentiation of hMSCs. 
These investigations will provide further understanding of nanosilicate-induced osteogenesis as 
well as further establish this mineral-based material as an alternative bioactive cue for bone 
regeneration.  
 
3.2 Materials and Methods 
3.2.1 Nanosilicate Dissociation in Physiologically Relevant pH  
The release of minerals from nanosilicates at physiologically relevant pH was monitored using 
Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) – Elemental Analysis (PerkinElmer 
NexION 300D). Nanosilicates (Laponite-XLG, BYK Ind, USA) were dispersed in distilled water 
of various pH (5.5, 7.4, and 10) and dialyzed against the same water over a period of 30 days at 
room temperature. At various time points (0.125, 1, 3, 7, 21 days) half of the dialysis water was 




nitric acid solution for ICP-MS analysis in which the concentrations of Li, Mg, and Si were 
determined. 
 
3.2.2 Evaluation of Nanosilicate Dissociation Products on hMSC Metabolic Activity 
All experiments were performed with hMSCs passage 5 or lower and cells were cultured in normal 
media (α-modified minimal essential media (AMEM); Hyclone), 16.5% fetal bovine serum (FBS; 
Atlanta Biological), and 1% penicillin/streptomycin (Gibco), unless otherwise stated. Mineral 
solutions of concentrations related to ICP results were prepared using lithium chloride (LiCl), 
magnesium sulfate (MgSO4), and sodium silicate (Na2O3Si). hMSCs were seeded in 96 well-plates 
at a density of 10,000 cells/cm2 and after 24 hours, were subjected to various mineral 
concentrations for an additional 24 hours. Minerals were then removed and an MTT assay 
(ATCC), was performed according to manufacture protocol. In addition, once desired 
concentrations were determined, an Alamar Blue assay (ThermoFisher) was performed at 1, 3, 7, 
and 14 days to quantify metabolic activity. For both MTT and Alamar Blue control groups 
consisted of untreated cells (negative) and cells treated with nanosilicates (positive). 
 
3.2.3 Evaluation of Nanosilicate Dissociation Products on hMSC Osteogenic Differentiation 
For osteogenic differentiation studies, hMSCs were similarly seeded in 96 well-plates at a density 
of 4,000 cells/cm2. After 24 hours, cells were treated with osteoconductive media (normal growth 
media supplemented with 10 mM β-glycerophosphate (Sigma-Aldrich) and 50 µM ascorbic acid 
(BDH Chemicals)) and the various mineral concentrations (4.49 µg/mL silicon, 0.067 µg/mL 
lithium, and 1.59 µg/mL magnesium) for an additional 48 hours; similar controls were used. After 




osteoconductive media and minerals for the remainder of the differentiation study. To analyze 
osteogenic differentiation, alkaline phosphatase (ALP) staining and kinetic activity were 
monitored along with matrix mineralization and quantification. First, hMSCs were fixed with 2.5% 
glutaraldehyde for 15-20 minutes. At 7 and 14 days, ALP staining was done using NBT/BCIP 1-
steps solution (Nitroblue tetrazolium/5-Bromo-4-chloro-3-indolyl phosphate; ThermoFisher) for 
30-60 minutes at room temperature. For quantification of ALP activity, hMSCs were incubated 
with alkaline phosphatase yellow (Sensolyte® pNPP ALP assay kit, AnaSpec). Using an 
automated plate reader (Tecan), ALP activity as a function of pNPP metabolism (ΔOD405) was 
measured and activity was normalized to DNA (picogreen, ThermoFisher). After 14 and 21 days, 
Alizarin Red staining (ARS; Electron Microscopy Sciences) was performed. The bound ARS, 
which is proportional to calcified matrix, and was quantified by dissolution in acetic acid (10%), 
neutralized by ammonium hydroxide (10%), and then measured in an automated plate reader 
(ΔOD405; Tecan). Both ALP and mineralized matrix were visualized with a stereomicroscope 
(Zeiss). 
 
For western blot, proteins were isolated after 14 days with Laemmli Buffer (0.2% bromophenol 
blue, 20% glycerol, 100 mM Tris HCl, 10% 2-mercaptoethanol, and 4% SDS). Protein samples 
were separated via gel electrophoresis (Invitrogen, Mini Gel Tank) and gels were then transferred 
(Invitrogen, iBlot 2) to a nitrocellulose membrane per manufacture protocol. Membranes were 
blocked with 5% BSA in PBST (1X PBS with 0.1% Tween20) for 30 minutes prior to antibody 
staining. B-actin, ALPL, osteocalcin (OCN), and osteopontin (OPN) primary antibodies were 
purchased from ThermoFisher, secondary HRP conjugated antibodies were purchased from Boster 




(SuperSignalTM West Pico PLUS Chemiluminescent Substrate, ThermoFisher) and imaged using 
LI-COR® 3600 C-Digit Blot Scanner. LI-COR software was used to quantify protein bands. 
Restoration and re-blocking with 5% BSA in PBST of the membranes was then done for further 
protein analysis.  
 
Gene expression was evaluated via quantitative reverse transcription polymerase chain reaction 
(qRT-PCR). After 14 days of culture, RNA was isolated with Roche, High Purity RNA Isolation 
kit following manufacture’s protocol. Nucleic material quality was evaluated via spectrometer 
absorbance ratio between 280/260 nm around 2.0. cDNA synthesis was then performed from 1 µg 
of RNA using Quanta Bio qScriptTM cDNA SuperMix following manufacture’s protocol. Primers 
were either designed via NCBI/Primer-BLAST or taken from previous literature and checked for 
quality via Integrated DNA Technologies’ OligoAnalyzer. Table 3-1 shows the primers designed 
and used. For qRT-PCR, SYBR Green Reagent (ThermoFisher) was used for amplification and 
samples were run and gene expression analyzed via QuantStudio 3 Real Time PCR 




Table 3-1. Primer Design for qRT-PCR 
Gene Forward Primer Reverse Primer 
GAPDH 5’-CCTTCATTGACCTCAACTACATGG-3’ 5’-TGGAAGATGGTGATGGGATTTCC-3’ 
ALPL 5’- ACC ATT CCC ACG TCT TCA CAT TT-3’ 5’-AGA CAT TCT CTC GTT CAC CGC C-3’ 







3.2.4 Statistical Analysis 
Statistical analysis was performed in GraphPad Prism. One-way analysis of variance (ANOVA) 
coupled with Tukey’s post-hoc were performed. Plots were graphed as mean and standard 
deviation and statistical significance is presented as *P-value < 0.05, **P-value < 0.01, ***P-
value < 0.001, and ****P-value < 0.0001. 
 
3.3 Results and Discussion 
3.3.1 Nanosilicate Dissociation Occurs at Physiologically Relevant pH 
Nanosilicates (Na+0.7[(Mg5.5Li0.3)Si8O20(OH)4]
-0.7) are composed of layered structures of 
octahedral magnesium and lithium ions sandwiched between tetrahedral silicon ions. Our central 
hypothesis is than in aqueous solutions with pH<9, nanosilicates dissociate into their nontoxic 
products (Li+, Si(OH)4, and Mg
2+). As previously discussed, nanosilicates are internalized by 
hMSCs predominantly via clathrin-mediated endocytosis and dissociation of nanosilicates likely 
occurs in the endosome due to the low pH (5.5).(201) In addition, the extracellular environment 
has pH~7.4 which could facilitate nanosilicate dissociation (Figure 3-1a). Therefore, we 
investigated nanosilicate dissociation at different relevant pH (5.5, 7.4, and 10) and determined the 
concentration of the dissociation products (Li+, Si4+, Mg2+) through Inductively-Coupled Mass 
Spectrometry (ICP-MS) (Figure 3-1b). Ion dissociation from a nanosilicate solution (50 ug/mL 
dispersed in 10 mL of deionized water) was monitored for 21 days at pH of 5.5 (mimicking 
intracellular pH), 7.4 (mimicking extracellular pH), and 10 (isoelectric point of nanosilicates). As 
expected, at the lower pH (5.5 and 7.4), higher concentrations of ions were present supporting our 
hypothesis that nanosilicate dissociation occurs at physiological pH. The concentration of lithium 




(5.89 ± 2.65 µg/mL) dissociation over 21 days at pH 5.5. While the concentration of lithium 
released was the lowest of the three ions across all pH, the percent released of lithium (63.94% at 
pH 5.5) was the greatest. Lithium ion release may occur more rapidly than magnesium or silicon 
ion release as lithium ions are bound by a hydroxide (OH-) as opposed to an oxide. Previous studies 
have reported that after Laponite is dispersed in water, OH- ions dissociate from the edge.(202) 
Specifically, at lower pH, the nanosilicates attempt to re-stabilize a basic pH via release of OH- . 
In addition, monovalent lithium is less stable than divalent magnesium or tetravalence silicon, so 
release of lithium occurs more rapidly. Silicon ion release (40.05% release at pH 5.5) was also 
observed to be greater than that of magnesium (25.02% release at pH 5.5), as silicon ions are 
present on the outer layer and are more susceptible to dissociation. After 21 days, the average 
percent released of individual ions at physiologically relevant pH (7.4 and 5.5) were 30.54% (4.49 
± 1.98 µg/mL) silicon, 49.27% (0.067 ± 0.03 µg/mL) lithium, and 18.17% (1.59 ± 0.85 µg/mL) 
magnesium. To further investigate the effect of these individual ions on cell behavior and 
osteogenic differentiation, these average percent released of the ions at physiological pH after 21 








Figure 3-1 Nanosilicate dissociation at physiological pH. (a) Nanosilicates begin to dissociate at pH<9 so 
once introduced to the extracellular (pH 7.4) and intracellular (pH 5.5) microenvironment, ion dissociation 
occurs. (b) Silicon, lithium, and magnesium ion release was monitored via ICP-MS, revealing significant 




3.3.2 Nanosilicate Dissociation Products Maintain hMSC viability 
Previous studies investigating hMSC viability after nanosilicate treatment have demonstrated the 
ability of nanosilicates to sustain viability.(37, 201) however, nanosilicate degradation products 
(Li+, Si4+, Mg2+) must also be investigated. Specifically, a broad range of silicon, lithium, and 
magnesium concentrations (0.001-10 mg/mL) were investigated to determine the effect of ions on 
cell viability and proliferation. Lithium and magnesium maintained 80% cell viability over a wide 




concentrations below 100 µg/mL (Figure 3-2a). Importantly, these viable concentrations were 
nearly 100-1000 times greater than those observed due to nanosilicate dissociation (4.49 µg/mL 
silicon, 0.067 µg/mL lithium, and 1.59 µg/mL magnesium) (Figure 3-1b). To investigate the effect 
of the individual ions within the nanosilicates on cell health, we treated hMSCs with the average 
release observed in ICP-MS: 30.54% (4.49 ± 1.98 µg/mL) silicon, 49.27% (0.067 ± 0.03 µg/mL) 
lithium, and 18.17% (1.59 ± 0.85 µg/mL) magnesium. While cells treated with nanosilicates were 
only treated once, the cells treated with individual ion solutions were replenished with those ion 
solutions every 3-4 days. Cell metabolic activity or viability after exposure to nanosilicates, 
individual ions, and the combination of ions was monitored via an Alamar Blue assay over 14 days 
(Figure 3-2b). No significant difference in viability was observed over time compared to the 
untreated control supporting nanosilicates and individual ions did not negatively affect hMSC 
health. These results support nanosilicate dissociation products can maintain cell viability as well 








Figure 3-2 (a) hMSC viability at various mineral ion concentrations. Concentrations of released ions fall 




3.3.3 Nanosilicate Dissociation Products Influence hMSC Osteogenic Differentiation 
To investigate the effect of individual ions (Li+, Si4+, Mg2+) on osteogenic differentiation of 
hMSCs, seeded cells were treated with the individual ions over 21 days. Ion concentrations were 
selected from ICP-MS data, in which 30.54% (3.49 ± 1.98 µg/mL) silicon, 49.27% (0.067 ± 0.03 
µg/mL) lithium, and 18.17% (1.59 ± 0.85 µg/mL) magnesium were released after 21 days. 
Individual ions were replenished every 3-4 days with media changes. After 7 and 14 days, alkaline 
phosphatase (ALP)—an early marker for osteogenic differentiation—production was evaluated 
via surface staining and an assay (Figure 3-3a,b). After 7 days, treatment with nanosilicates, 
silicon, and the combination of ions resulted in nearly a two-fold increase in ALP production 




resulted in similar ALP protein production to the nanosilicates. In addition, after 14 days of 
treatment, individual ions along with the combination ions resulted in significantly greater ALP 
production compared to the untreated control (***p-value < 0.001) (Figure 3-3b). Likewise, matrix 
mineralization or calcium deposit was monitored after 21 days (Figure 3-3a). Quantification of 
mineralization revealed treatment with silicon (***p-value < 0.001), the combination of ions (**p-
value < 0.01), and nanosilicates (*p-value < 0.05) significantly increased matrix mineralization 
compared to the untreated control (Figure 3-3c). Similarly, silicon treatment resulted in 
significantly greater production of mineralization compared to lithium and magnesium treatment 
(***p-value < 0.001).  
 
In addition, osteo-specific protein production was monitored via western blot. Specifically, ALP, 
osteocalcin (OCN), and osteopontin (OPN), and collagen type I (COL1A1) expression were 
evaluated after 14 days (Figure 3-3c). Protein bands were quantified and the addition of silicon 
significantly increased OCN and OPN production compared to the untreated control nearly three-
fold and ALP production nearly two-fold (Figure 3-3d). Similarly, nanosilicate treatment resulted 
in nearly two-fold protein expression of OPN and ALP and three-fold expression of OCN 
compared to untreated control. Alternatively, while magnesium increased OCN production nearly 
two-fold in comparison to the control, lithium and magnesium treatment resulted in limited 
expression of ALP and OPN. While COL1A1 protein expression after 14 days was not as distinct 
as other proteins, it is a later marker for osteogenic differentiation. However, treatment with 
nanosilicates and silicon did result in nearly 15-fold COL1A1 production compared to the 





While silicon on its own had a significant effect on hMSC differentiation, this could result from 
the high treatment concentration of silicon in comparison to the lower treatment concentrations of 
lithium and magnesium. In addition, these ion concentrations were added externally to the hMSCs 
compared to the release of ions from the nanosilicates that occurs in the endosome. The local 
concentration of released lithium and magnesium within the cell most likely has a greater effect 
than the external addition of the low concentration of lithium or magnesium. Overall, treatment 
with the combination of ions resulted in statistically similar ALP production and matrix 
mineralization compared to the nanosilicates. While osteo-specific protein production after 
treatment with the combination of ions has yet to be assessed via western blot, based on ALP 
production and matrix mineralization, similar protein production to nanosilicates and silicon is 
expected. Importantly, this evaluation of osteo-specific proteins and matrix production support 
that the chemical makeup of the nanosilicates and their subsequent release do play a pivotal role 








Figure 3-3 hMSC osteogenic differentiation. (a) ALP and matrix mineralization production after treatment 
with ions for 7, 14 and 21 days (Scale bar 500 µm). (b) ALP activity of individual ions compared to 
nanosilicates and all ions. (c) Quantification of mineralized matrix after 21 days. (d) Western blot of osteo-
specific proteins after 14 days. (e) Quantification of protein expression from western blot normalized to β-





In addition, to evaluation of protein production after individual ion treatment, the effects of the 




assessed after 14 days (Figure 3-4a). ALP gene expression was evaluated and a similar trend in 
gene fold change expression to protein expression was observed. Specifically, treatment with 
nanosilicates and the combination of ions resulted in similar fold changes of 3.12 and 2.82, 
respectively. Silicon, lithium, and magnesium also increased ALP expression 2.51, 2.49, and 1.84, 
fold-change, respectively. COL1A1 gene expression was also evaluated, and similar to the 
observed protein expression, gene expression was low for all treatment groups. Specifically, the 
fold-change in COL1A1 expression was ≤ 1.5 for all treatment groups. Although low, the presence 
of COL1A1 gene expression is promising as it is the most abundant collagen in bone.  
 
To further evaluate transcriptomic changes to hMSCs after treatment with individual ions and 
obtain a holistic view of these changes, whole-transcriptome sequencing (RNA-seq) was used. 
Preliminary evaluation revealed individual ions did not elicit as pronounced changes in gene 
expression as the nanosilicates, as evidenced by the heat map (Figure 3-4c); however, the genes 
that are significantly and differentially expressed will be further investigated and will help in 
pinpointing specific pathways affected. Further investigation of genetic targets of these individual 
ions will also aid in understanding mechanisms behind the innate osteoinductivity of nanosilicates. 
For example, from previous studies investigating the effects of lithium and silicon on osteogenic 
differentiation, activation of Wnt signaling was identified.(160, 163) With RNA-seq we expect to 
identify genes and subsequent pathways related to Wnt based on these previous studies. 
Importantly, information gathered from these individual ions can be used in future studies to design 








Figure 3-4 Comparison of genetic expression between different hMSC treatment groups. (a) Gene 
expression evaluated via qRT-PCR after 14 days, fold-change compared to untreated hMSCs. (b) Principal 
component analysis graph displaying genetic distance/relatedness across different ion and nanosilicate 









Nanosilicate dissociation into bioactive ions at physiological pH was identified and the treatment 
of hMSCs with the dissociation products (Li+, Mg2+, and Si4+) stimulated osteogenic 
differentiation. While individual ions influenced hMSC osteogenic differentiation, the 
combination of the three ions elicited the greatest effect compared to the nanosilicates, supporting 
that the biochemical property of nanosilicates contributes to their innate osteoinductivity. Further 
investigation of hMSC responses to individual ions at the transcriptome level using RNA-seq will 
help further elucidate roles of these ions in modulating hMSC behavior and differentiation. 
Investigation of bioactive nanomaterials holds great promise for future tissue regeneration 
strategies as these materials have the potential to replace traditional bioactive cues. In addition, 
these investigations will aid in designing specific mineral-based nanomaterials in the future to 





4. LOCALIZED THERAPEUTIC DELIVERY FROM 2D NANOSILICATES DIRECTS 




Clinical strategies involve the administration of inductive molecules such as recombinant human 
bone morphogenetic protein 2 (rhBMP2) or transforming growth factor-beta3 (TGF-β3) to enhance 
tissue formation.(207, 208) While successful regeneration has been observed, this is at the cost of 
supraphysiological doses of growth factor (1.5 mg/mL)(209), stemming from rapid clearance from 
the injury site and short half-lives of 7-16 minutes due to proteolysis in vivo.(210, 211) 
Furthermore, growth factors like, endogenous BMPs are typically found in the body at a 
concentration of less than 2 g/mg.(212, 213) Recent clinical studies have demonstrated 
significant adverse effects following use of supraphysiological doses of including heterotopic 
tissue formation (spatially uncontrolled tissue formation), osteolysis, and inflammation.(214-216) 
These adverse effects are typically attributed to poor localization and rapid release of large 
amounts of growth factor.(217) Thus, there is a clinical need to develop an efficient biomolecule 
delivery vehicle that can result in sustained and prolonged release to reduce the effective dose 
towards physiological levels. 
 
                                                 
* Cross, L.M.; Carrow, J.K., Singh K.A.; Gaharwar A.K. “Sustained and Prolonged Delivery of 
Protein Therapeutics from 2D Nanosilicates to Direct Differentiation of Human Mesenchymal 




Sustained release of low concentrations of growth factor molecules would minimize the side 
effects of excessive dosages.(217-219) Several strategies have emerged to reduce the dosage of 
growth factors, while maintaining therapeutic efficacy.(220-222) However, most of these 
approaches still incorporate relatively high dosages of growth factors (micrograms-milligrams), 
which can be costly. Here, we describe a nanosilicate-based platform to minimize the 
concentration of delivered therapeutic, while maintaining bioactivity and effectiveness. 
Nanosilicates (Na+0.7[(Mg5.5Li0.3)Si8O20(OH)4]
-0.7, Laponite® XLG), a two-dimensional (2D) 
nanomaterial, have been investigated for various biomedical applications including regenerative 
engineering and drug delivery.(38, 141, 223, 224) Our recent studies have demonstrated high 
cytocompatibility of nanosilicates with hMSCs.(138, 201) Nanosilicates readily attach to the cell 
membrane and are internalized by hMSCs via clathrin-mediated endocytosis.(184, 185, 225) In 
addition, nanosilicates have also shown to upregulate osteochondral-related genes and protein such 
as RUNX2, osteocalcin, aggrecan, and COMP, as well as production of mineralized matrix.(37, 
139)  
 
Along with their inherent bioactivity, the disk-shaped nanosilicates particles generate a permanent 
negative charge on each face (via the release of Na+ in solution) and a positive charge along the 
edge (via the protonation of OH- groups).(136, 202, 226) The dual charge of nanosilicates 
facilitates a wide range of possible interactions with proteins and therapeutics; importantly, these 
particles have previously been investigated for drug delivery applications.(223, 227-230) 
Specifically, cationic drugs can be immobilized by the exchangeable sodium cations of the 
nanosilicates.(223, 231) While these previous studies have demonstrated the  ability of 




explore the inherent bioactivity of nanosilicates. Similarly, other studies have utilized nanosilicates 
for growth factor delivery; however, these studies use large concentrations of the nanosilicates and 
deliver the growth factors via a clay gel.(232, 233) No studies have investigated growth factor 
delivery via individual nanosilicates. 
 
Here we demonstrate the ability of nanosilicates to prolong the release of physiologically relevant 
concentrations of rhBMP2 and TGF-β3 and synergistically contribute towards osteogenic and 
chondrogenic differentiation of hMSCs, respectively. We will investigate the binding efficacy of 
protein to the nanosilicates, the time-dependent release of model protein from the nanosilicates, 
and we will also evaluate the osteochondral potential of the nanosilicate-rhBMP2 or TGF-β3 co-
delivery via osteochondral-related proteins and ECM production. Utilizing the nanosilicates as a 
delivery vehicle could be a potential therapy to augment the inherent bioactivity of nanosilicates. 
In addition, nanosilicate delivery of biomolecules could reduce overall costs by reducing growth 
factor concentration as well as minimize the negative side effects observed in use of 
supraphysiological dose of growth factors orthopedic regeneration strategies.  
 
4.2 Materials and Methods 
4.2.1 Nanosilicate Characterization  
Nanosilicates (Laponite® XLG) were obtained from BYK additives. Atomic force microscopy 
(AFM), X-ray photoelectron spectroscopy (XPS), and attenuated total reflectance Fourier 
transform infrared spectroscopy (ATR-FTIR) were performed. Nanosilicate thickness was 
measured via AFM tapping mode (Bruker Dimension Icon Nanoscope), and analyzed with 




(Omicron XPS system with Argus detector), specifically analyzing oxygen (O 1s), silicon (Si 2p), 
magnesium (Mg 2s, 2p), lithium (Li 1s), and sodium (Na 1s) binding energies. ATR-FTIR was 
performed on nanosilicate powder with a Bruker vector-22 FTIR spectrophotometer (PIKE 
Technologies).  
 
4.2.2 Protein-Nanosilicate Interactions 
The hydrodynamic size and zeta potential of nanosilicate-protein (fetal bovine serum, Atlanta 
Biologicals) solutions were measured at 25°C using a Zetasizer Nano ZS (Malvern Instrument, 
U.K.) equipped with a He-Ne laser. Particle size was further investigated with transmission 
electron microscopy (TEM). The binding efficiency of nanosilicates to protein was determined 
using a model protein: fluorescein isothicyanate labelled bovine serum albumin (FITC/BSA, 
Sigma-Aldrich). 100 µg/mL of FITC/BSA was mixed for 1 hour with various concentrations of 
nanosilicates (0, 1, 10, 50, 100, 500, 1000 µg/mL) and then centrifuged to separate unbound 
protein. The supernatant was collected and measured using NanoDrop (495 nm excitation, 530 nm 
emission; NanoDrop 3300 Florospectrometer, Thermo Fisher Scientific) to determine binding 
efficiency.  
 
4.2.3 In vitro Protein Release  
The release profile of protein bound to nanosilicates was determined using a model protein bovine 
serum albumin (BSA, Sigma-Aldrich). Nanosilicate:BSA conjugates were made in phosphate 
buffered serum (PBS) and mixed for 1 hour to ensure binding. Samples were dialyzed (Float-A-
Lyzer 100 kD MW, Spectrum) against PBS and samples were collected at various time points. The 




protocol. 1-anilinonaphthalene-8-sulfonate (ANS) Assay was performed following previously 
described protocol.(234) Briefly, an ANS stock solution was prepared and filtered. The stock 
solution concentration was then determined via an absorbance reading at 350 nm and using an 
extinction coefficient of 50000 (M/cm)-1. Protein samples were diluted and combined with ANS 
in a buffer of 10 mM Tris HCl, pH 7.4. Fluorescence from ANS was then measured in a plate 
reader at an excitation wavelength of 370 nm and an emission wavelength scan from 400-620 nm. 
 
4.2.4 In vitro Osteogenic Differentiation  
All in vitro experiments were performed with human mesenchymal stem cells (hMSCs) passage 5 
or lower, obtained from Lonza. hMSCs were cultured in osteoconductive media (α-modified 
minimal essential media (αMEM, Hyclone), 16.5% fetal bovine serum (FBS, Atlanta Biological), 
and 1% penicillin/streptomycin (Gibco), supplemented with 10 mM β-glycerophosphate (Sigma-
Aldrich) and 50 µM ascorbic acid (BDH Chemicals). The osteogenic differentiation potential of 
nanosilicate-recombinant human bone morphogenetic protein 2 (rhBMP2, EMD-Millipore) 
complexes was evaluated in vitro using hMSC 2D culture. hMSCs were seeded at a density of 
4,000 cells/cm2 in a 96-well plate and cultured in osteoconductive media for 7, 14, and 21 days. A 
negative control of untreated cells and a positive control of rhBMP2 (10 ng/mL) were used. Sample 
groups consisted of nanosilicates (100 µg/mL) and nanosilicate-rhBMP2 (100 µg/mL-10ng/mL). 
hMSCs were treated with nanosilicates and nanosilicate-rhBMP2 for 48 hours; hMSCs treated 
with exogenous rhBMP2 were treated with additional rhBMP2 every media change (every 3-4 
days). To analyze osteogenic differentiation, conventional osteogenic assays were performed. 
Specifically, alkaline phosphatase (ALP) staining and kinetic assay, alizarin red staining and 




Prior to staining, hMSCs were fixed with 2.5% glutaraldehyde for 15-20 minutes. ALP staining 
was performed at 7 and 14 days with NBT/BCIP 1-steps solution (Nitroblue tetrazolium/5-Bromo-
4-chloro-3-indolyl phosphate, Thermo Fisher) for 30-60 minutes at room temperature. For ALP 
kinetic assay, cultures were incubated with alkaline phosphatase yellow (Sensolyte® pNPP ALP 
assay kit, AnaSpec). ALP activity as a function of pNPP metabolism (ΔOD405) was measured 
using automated plate reader and activity was normalized to DNA (picogreen, Thermo Fisher). 
Alizarin Red staining (ARS, Electron Microscopy Sciences) was performed after 14 and 21 days 
which binds to calcium; bound ARS is proportional to calcified matrix and was quantified by 
elution in acetic acid (10%), neutralized by ammonium hydroxide (10%), and 
spectrophotometrically measured by absorbance at 405 nm. ALP and ARS staining were visualized 
with stereomicroscope (Zeiss). 
 
For immunostaining, hMSCs were fixed (10% formalin) then incubated in blocking solution (1% 
BSA in PBS) for 30 minutes. Samples were incubated with primary antibody for 1 hour at room 
temperature, then washed and incubated with secondary antibody for 1 hour. Samples were imaged 
with confocal microscope (Leika TCS SP5).  
 
For Western Blot analysis, hMSC protein samples were isolated via a Laemmli buffer (10% 2-
mercaptoethanol, 20% glycerol, 100 mM Tris HCl, 4% SDS, and 0.2% bromophenol blue). Protein 
samples were separated via gel electrophoresis (Mini Gel Tank; Invitrogen) and the gel was 
transferred (iBlot2; Invitrogen) to a nitrocellulose membrane. 5% BSA in PBST (0.1% Tween 20 
in PBS) was used to block membranes for 30 minutes then processed to investigate specific 




antibodies (Thermo Fisher) and HRP conjugated secondary antibodies (Boster Bio) were used. 
After incubation with antibodies according to manufacturer’s protocol, membranes were 
developed (SuperSignal West Pico PLUS Chemiluminescent Substrate; Thermo Fisher) and 
imaged with LI-COR 3600 CDigit Blot Scanner and bands were quantified via LI-COR software. 
Restoration and subsequent re-blocking were performed for additional protein analysis.  
 
4.2.5 Spheroid Culture 
For spheroid culture, hMSCs were cultured in basal media and collected no later than P4. 
Spheroids were created through centrifugation of cell suspensions to result in 106 cells per 
spheroid for GAG quantification and 2 x 106 cells per spheroid for histology. During 
centrifugation (500xg, 10 min), various treatments were added to media, specifically 
nanosilicates (50 µg/mL), (211) TGF-β3(Boster Bio, 10 ng/mL), or a solution of premixed 
nanosilicates/TGF-β3 at equivalent concentrations. Control cells received no external treatment. 
Media was replaced every 3-4 days. After 21 days of culture, spheroids were washed in PBS and 
fixed using 10% neutral buffered formalin for 2 hours. To quantify histological stains, images 
were processed with ImageJ software. Images were modified into an RGB greyscale stack. Color 
thresholding was applied equally over images within a stain cohort. Areas meeting color 
threshold were selected, quantified, and subsequently normalized to the total area of the 
spheroid. For the quantification of sulfated GAGs, a dimethylmethylene blue (DMMB, Sigma 
Aldrich) assay was utilized. Briefly, samples were collected at Day 3 and Day 21. Following 
washing with PBS, spheroids were enzymatically digested with papain at 60 °C overnight. The 




NaCl (2.37 mg/mL) dissolved in deionized water and maintained at pH 1.5 using 0.1M HCl. A 
standard curve was generated from chondroitin sulfate (Alfa Aesar). 
 
4.2.6 Statistical Analysis 
Plots are represented as mean and standard deviation and statistical analysis was performed using 
a one-way analysis of variance (ANOVA) with a Tukey’s post-hoc with GraphPad Prism software. 
The statistical significance is presented as *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001, 
and ****P-value < 0.0001. 
 
4.3 Results and Discussion 
Nanosilicates (Laponite XLG) are two-dimensional charged particles, approximately 1-2 nm thick 
and 25-30 nm in diameter (Figure 4-1a). The material properties of these nanosilicates have been 
extensively characterized in our previous papers.(201) Here, we investigated nanosilicate size 
distribution via transmission electron microscopy (TEM) and atomic force microscopy (AFM). 
TEM revealed uniform disk-shaped particles, and AFM images show that nanoparticle thickness 
was ~1.5 nm (Figure 4-1a,b). Surface characteristics of nanosilicates were also evaluated via ATR-
FTIR, confirming the presence of O-Si-O stretching and bending around 1000 and 700 cm-1 , 
respectively (Figure 4-1c).(235, 236) Utilizing x-ray photoelectron spectroscopy (XPS), the 
presence of sodium, oxygen, silicon, magnesium, and lithium were identified, supporting chemical 
makeup of the nanosilicates (Na+0.7[(Mg5.5Li0.3)Si8O20(OH)4]
-0.7) (Figure 4-1d). In agreement with 
the empirical formula of nanosilicates, the XPS data supports oxygen as the most prevalent ion 
followed by silicon. As XPS and ATR-FTIR are surface techniques and the faces of the 




on the negative face of the nanosilicates. Additionally, the presence of O-Si-O bending and 
stretching on the surface, exposes the two-lone pair of electrons on each oxygen atom, contributing 
to the negative surface charge. Similarly, the positive edge of the nanosilicates stems from the 
protonation of OH- groups. Importantly, the negatively charged faces and positively charged edges 






Figure 4-1 Physical characterization of nanosilicates. (a) TEM revealed size of two-dimensional 
nanosilicates. (b) AFM indicated the thickness of nanosilicates ~1-2 nm. (c) ATR-FTIR showed 
characteristic peaks at ~1000 and 700 nm representing Si-O bending and stretching, respectively. (d) XPS 
showed chemical composition of nanosilicates as shown by the binding energies for oxygen, silicon, 




When nanosilicates are introduced into a physiological environment, their interactions with 




The nanoparticle-protein complex can influence cellular transport as well as influence surface 
receptors and cellular pathways. (165, 237, 238) Therefore, these strong electrostatic interactions 
can be used to bind therapeutic growth factors and facilitate prolonged delivery. We previously 
determined (via whole-transcriptome sequencing) that nanosilicates trigger membrane targeting 
and can affect several signaling pathways related to growth factor stimulus and osteochondral-
specific pathways.(201) Further gene ontological (GO) analysis has indicated that nanosilicate 
treatment of hMSCs results in the activation of “cellular response to growth factor stimulus,” 
thereby conditioning the hMSC population for a growth factor treatment.(201) Based on this 
information, nanosilicates can be used to delivery therapeutics near the cell membrane or in the 
cytosol. For example, growth factors such as rhBMP2 or TGF-β3 can be electrostatically bound to 
nanosilicates to enhance their inductive capability, thereby reducing the overall dose of growth 
factor. It is expected that the combination of growth factor with bioactive nanosilicates will allow 
for enhanced and synergistic osteogenic and chondrogenic differentiation in hMSCs.  
 
4.3.1 Nanosilicates Strongly Interact with and Sequester Proteins 
We investigated nanosilicate-protein interactions using fetal bovine serum (FBS). The dual charge 
of nanosilicates allows for a variety of electrostatic interactions or binding with serum proteins 
(Figure 4-2a). The size and charge of the resulting nanosilicate-FBS complexes were investigated, 
and TEM images revealed the presence of protein surrounding the nanosilicates in samples where 
FBS had been introduced. Further investigation with dynamic light scattering (DLS) confirmed 
this result; a significant increase in particle sized was observed in the nanosilicate-protein complex 
(~50 nm) compared to nanosilicates along (~28 nm) (Figure 4-2b). Similarly, unaltered 




nanosilicate-protein complexes formed in FBS (-23 ± 1 mV), indicating regions of the negatively 
charged faces were indeed coated with protein (Figure 4-2b). Importantly, while the complex’s 
zeta potential shifted significantly compared to the nanosilicates, the value remained within the 
range of particle stability. A previous study investigated silica nanoparticle interactions with serum 
proteins and observed a similar shift in resulting particle size and zeta potential.(239) These results 
demonstrate that nanosilicates can strongly interact with proteins and/or therapeutic molecules.  
 
4.3.2 Nanosilicates Strongly Bind and Release Proteins 
Nanosilicate-protein binding efficacy and release kinetics were investigated using model proteins, 
specifically bovine serum albumin (BSA). Utilizing a fixed concentration of BSA labelled with 
fluorescein isothiocyanate (FITC/BSA, 100 µg/mL) and various concentrations of nanosilicates 
(0-1000 µg/mL) binding efficacy of the nanosilicates was examined. Approximately 100% binding 
was observed for a mass ratio of nanosilicates:FITC/BSA above 5:1 (Figure 4-2c). This indicates 
that the concentration of nanosilicates must be at least five times greater than the concentration of 
protein or therapeutic to attain the most efficient binding. Previous studies also support the ability 
of nanosilicates to bind proteins or small molecules. For example, one study demonstrated 
doxorubicin simply mixed with a nanosilicate suspension allowed for doxorubicin binding or 
encapsulation through ion exchange in the interlayered space of the dispersed nanosilicates.(228, 
240) Interestingly, even non-ionic drugs such as dexamethasone have also recently been 








Figure 4-2 Nanosilicates strongly interact with proteins. (a) Schematic of protein interactions with 
nanosilicates. TEM images of nanosilicates in fetal bovine serum (FBS) solution. (b) DLS of nanosilicates 
(nSi) and nanosilicates with FBS (nSi-FBS) demonstrating shift in particle size with addition of protein 
solution. Zeta potential of nanosilicates and nanosilicates with FBS; once in contact with protein, particle 
charge shifts to be more positive (***P-value < 0.001). (c) Percent binding efficiency of nanosilicates to 
protein; nearly 100% binding observed at a ratio of nanosilicates to protein of 5:1. (d) ANS assay 
demonstrating no change in protein’s secondary structure when bound to nanosilicates as indicated by 
minimal shift in fluorescent peak compared to completely denatured protein (positive control). (e) Early 




In addition to binding efficiency, the retained structure of the bound protein or therapeutic is 




Therefore, utilizing 1-anilinonaphthalene-8-sulfonate (ANS), we assessed changes in 
conformation of the bound protein.(241, 242) In this assay, the fluorescent dye binds to 
hydrophobic regions of the protein and so changes in fluorescence signal indicate a change in the 
exposed hydrophobic regions due to protein conformation change. No significant change in 
fluorescence was observed once protein was bound to nanosilicates compared to isolated protein. 
This indicated a minimal effect of nanosilicate binding on protein structure, suggesting that protein 
activity is retained (Figure 4-2d). Importantly, these results support previous studies that report 
negatively charged nanoparticles do not perturb protein structure.(237)  
 
The release of protein from nanosilicates was monitored over a course of 30 days under 
physiological conditions. After an initial burst release of loosely bound protein within the first 12 
hours, nanosilicates displayed sustained release of bound BSA (Figure 4-2e). The release kinetic 
was fit to a two-phase association model with an R2 of 0.98, indicating a good fit for this release 
profile. The rate constant for long-term release was calculated as 0.001724 days-1. This study 
supports our hypothesis that nanosilicates can be used as a vehicle for prolonged delivery of 
therapeutics. As 100% release was not observed, we believe that some protein may remain bound 
to the nanosilicates. In addition, released protein was analyzed via an ANS assay to investigate 
retained protein structure. Results indicated similar shifts in fluorescence compared to unmodified 
protein suggesting that the bioactivity of released protein was retained. These studies support the 





4.3.3 Nanosilicate-rhBMP2 Delivery Promotes Production of Osteo-Related Proteins 
The activity of released growth factor (rhBMP2) from nanosilicates was assessed using in vitro 
studies. Nanosilicates/rhBMP2 (100 µg/mL: 10 ng/mL) were subjected to seeded hMSCs and 
osteogenic differentiation was monitored over four weeks. We used untreated hMSCs, 
nanosilicates (100 µg/mL) treated hMSCs, and exogenous rhBMP2 treated hMSCs as controls. 
hMSCs treated with nanosilicate/rhBMP2 were treated for 48 hours, after which media was 
changed with osteoconductive media every 3-4 days, while exogenous rhBMP2 treated hMSCs 
were provided with fresh osteoconductive media containing rhBMP2 (10 ng/mL) every 3-4 days. 
After 7 and 14 days of culture, the production and activity of alkaline phosphatase (ALP, an early 
marker for osteogenic differentiation) was evaluated. Early on, an increase in alkaline phosphatase 
staining was observed in hMSCs treated with nanosilicate/rhMBP2 compared to hMSCs treated 
with exogenous rhBMP2 (Figure4-3a). ALP activity was also quantified and a significant increase 
in ALP production was observed in the nanosilicate, nanosilicate-rhBMP2, and exogenous 
rhBMP2 groups compared to untreated controls after 7 and 14 days of culture (Figure 4-3b). 
Similarly, ALP protein production was monitored via western blot after 14 days and an increase 
in protein bands were observed in the groups containing exogenous and nanosilicate/rhBMP2 
(Figure 4-3c). Notably, the production of ALP in hMSCs treated once with nanosilicate/rhBMP2 
(10 ng/mL) was comparable or greater than that of multiple treatments with exogenous rhBMP2 








Figure 4-3 rhBMP2 bound to nanosilicates enhances alkaline phosphatase production. Nanosilicates and 
rhBMP2 bound to nanosilicates were delivered once while exogenous rhBMP2 was delivered every media 
change (every 3-4 days). (a) rhBMP2 bound to nanosilicates enhances alkaline phosphatase protein 
production compared to exogenous rhBMP2. (b) ALP activity after 7 and 14 days of culture. After 7 days, 
rhBMP2 delivery via nanosilicates increased production significantly (*P-value < 0.05, **P-value < 0.01, 
****P-value < 0.0001. (c) Western blot of ALP after 14 days reveals an increase in protein production for 




In addition, the osteo-specific marker osteocalcin, one of the most abundant non-collagenous 
proteins in bone,(243) was evaluated via immunostaining and western blot analysis after 14 days 
of culture. Osteocalcin expression was greater in the hMSCs treated with nanosilicate/rhBMP2 




bands for osteocalcin revealed a significant increase in protein production for hMSCs treated with 
exogenous and nanosilicate/rhBMP2 compared to untreated control (Figure 4-4c). Osteopontin, 
which is important for biomineralization,(244) was expressed in all groups except the untreated 
control (Figure 4-4b). A distinct band for COL1A1 was observed in nanosilicate/rhBMP2 treated 
hMSCs (Figure 4-4d), compared to nanosilicate and exogenous rhBMP2 treated hMSCs. Further 
quantification of the band intensity supported the significant increase in COL1A1 production in 
the nanosilicate/rhBMP2 group compared to all other treatments. While previous studies have 
shown nanosilicates to increase COL1A1 production,(201) the significant increase in protein 
production with nanosilicate/rhBMP2 could have masked detection in the nanosilicate and 
exogenous rhBMP2 groups. Regardless, COL1A1 is very abundant in bone tissue so the increase 
in the protein production with treatment of both rhBMP2 and nanosilicates supports the synergistic 








Figure 4-4 Sustained delivery of rhBMP2 promotes osteo-specific protein production. (a) Osteocalcin 
production enhanced by dual delivery of nanosilicates and growth factor after 14 days of culture. (b) 
Western blot of osteocalcin and osteopontin after 14 days revealed increase in protein production in all 
treatment groups compared to the control. In addition, collagen type I (Col1A1) production was increased 
in the nanosilicate/rhBMP2 treated hMSCs. (c) Quantification of osteocalcin showed a significant increase 
in exogenous and nanosilicate/rhBMP2 groups compared to the control (**P-value < 0.01). In addition, 
quantification of intensity values for Col1A1 revealed a significant increase in protein production for 




4.3.4 Nanosilicate-rhBMP2 Delivery Stimulates Mineralized ECM formation by hMSCs 
Finally, the one-time delivery of nanosilicate/rhBMP2 significantly increased matrix 
mineralization or calcium deposit compared to multiple treatments of rhBMP2 alone. Alizarin Red 
staining revealed an increase in calcium deposit from 14 to 28 days (Figure 4-5a). After 14 days 
of culture, there was evidence of calcified matrix or bone nodules in the hMSC culture treated with 
nanosilicate/rhBMP2. Previous studies utilizing nanosilicates have also shown that these particles 




hMSCs treated with exogenous rhBMP2 at 21 and 28 days, these nodules were not present 
suggesting the dual delivery has a greater effect on osteogenic differentiation. Matrix 
mineralization at 14, 21, 28 days were quantified (Figure 4-5b). A significant increase in calcium 
production was observed in the nanosilicate/rhBMP2 groups across all days. At the later time 
points of 21 and 28 days, hMSCs treated with exogenous rhBMP2 also produced significant 
calcium deposit compared to control and nanosilicate treated groups.  
 
The observed increase in osteo-specific markers and mineralized matrix production with the 
nanosilicate bound rhBMP2 not only supported retained rhBMP2 activity, but more importantly 
this dual delivery system induced synergistic and enhanced osteogenic differentiation. In addition, 
the dosage of rhBMP2 (10 ng/mL) delivered with the nanosilicates was significantly less than 
concentrations typically administered in in vitro studies; for example, previous studies have 
incorporated doses greater than 100 ng/mL.(220, 221, 232) While previous studies have utilized 
nanosilicates for delivery of growth factors, these studies have encapsulated growth factors within 
a nanosilicate gel or used the gel to sequester exogenous growth factor rather than binding them 
to the individual particles.(144, 232) Clay gels with encapsulated rhBMP2 displayed decreased 
bioactivity compared to groups with clay gels sequestering exogenous rhBMP2.(144, 232) In 
addition, the previous study merely seeded cells on top of fabricated gels, limiting cellular 
interactions with individual nanosilicates.(232) In the present study, nanosilicates with low dosage 
of rhBMP2 (10 ng/mL) were directly applied to hMSC culture; this allowed for hMSCs to interact 
with individual particles, and the delivery of rhBMP2 can be localized to the cell. Importantly, this 
dual delivery occurred only once during the study, as was only ~10% of the continual rhBMP2 




system provides an alternative and synergistic treatment for directing hMSC osteogenic 
differentiation and subsequently bone regeneration, minimizing both the cost and negative side 





Figure 4-5 Sustained delivery of rhBMP2 from nanosilicates increases matrix mineralization. (a) Matrix 
mineralization or calcium deposit was significantly enhanced by dual delivery after 14 and 21 days 
compared to exogenous growth factor alone. Similarly, after 28 days, staining for mineralized matrix 
between exogenous rhBMP2 control and delivered rhBMP2 was comparable. (b) Quantification of calcium 
deposit after 14,21, and 28 days revealed a significant increase in deposit with the delivery of rhBMP2 via 







4.3.5 Nanosilicates-TGF-β3 Delivery Promotes Chondrogenic Differentiation of hMSCs 
To investigate the ability of nanosilicates to deliver TGF-β3 for chondrogenic differentiation of 
hMSCs, we modified the culture conditions of the hMSCs. Specifically, hMSCs were placed into 
three-dimensional (3D) spheroids to recapitulate the cell-cell interactions found in native cartilage 
(Figure 4-6a). Similar to the previous studies, cells were cultured in the absence of growth-factor 
unless specified otherwise. Over the course of one week, untreated hMSCs, hMSCs treated with 
nanosilicates, and hMSCs treated with exogenous TGF-β3 displayed minimal differences 
regarding matrix synthesis with both sulfated glycosaminoglycans (GAGs, Alcian Blue) and 
collagens (Trichrome). Interestingly, the delivery of TGF-β3 bound to nanosilicates appeared to 
improve chondrogenic behavior as early as seven days following spheroid formation. At later 
culture times (21 days), to indicate successful induction into a cartilage phenotype, histology was 
performed to monitor matrix component synthesis (Figure 4-6b,c). Alcian Blue stains indicated an 
increase in sulfated GAG production within the spheroid. Quantification of this staining through 
color thresholding in image software ImageJ revealed a significant increase in matrix production 
for spheroids with nanosilicate/TGF-β3 delivery (Figure 4-6b). While continuous delivery of TGF-
β3 alone increased production of cartilage-specific matrix, the co-treatment of nanosilicates with 
TGF-β3 provided the greatest stimulation towards the chondro phenotype at 10-fold lower 
concentration of TGF-β3 (Figure 4-6c). This study support our previous work in which we 
demonstrated an increased cartilage-specific gene due to nanosilicate treatment alone.(201) From 
our previous work utilizing whole-transcriptome sequencing, we also observed that nanosilicates 
activated pathways related to TGF-β family proteins (e.g. response to transforming growth factor 








Figure 4- 6 Sustained delivery of TGF-β3 from nanosilicates to hMSC spheroids. (a) Schematic of spheroid 
culture setup and delivery of TGF-β3 via nanosilicates. Quantification of glycosaminoglycan production 
after 3 and 21 days. (b) Alcian blue staining after 7 and 21 days across treatment groups, an increase in 
staining or sulfated glycosaminoglycan production in samples treated with TGF-β3 bound to nanosilicates 







Our nanosilicate/growth delivery system exhibits great promise for future orthopedic regeneration 
strategies. To assist in localization in vitro, the system could easily be incorporated into various 
tissue engineering constructs, including pre-fabricated scaffolds currently utilized to deliver 
therapeutics, like a collagen sponge or gel putty. Incorporation of nanosilicates with a collagen 
sponge of putty could prolong the delivery of entrapped growth factors and thus reduce the overall 
concentration. Moreover, nanosilicates can also be combined with a variety of natural and 
synthetic polymeric hydrogel systems including gelatin, kappa carrageenan, and poly(ethylene 
dioxide) for sustained and prolonged delivery of therapeutic proteins. These nanocomposite 
systems have been investigated for both injectable systems and 3D printed constructs.(41, 227, 
245, 246) By localizing and patterning therapeutic protein, regionalized differentiation of stem 
cells on gradient scaffolds can be obtained to mimic the osteochondral interface.(246) Moreover, 
this technology can be extended to load-bearing applications by using in conjunction with an 
interbody fusion cage or by combining nanosilicates with biodegradable implants made from poly 
(propylene fumarate) or poly(L-lactic acid). 
 
4.4 Conclusion 
Our nanosilicate-based platform demonstrates the potential for superior orthopedic tissue 
engineering by reducing the required dose of growth factors. Due to the dual-charged and disc-
shaped characteristics of nanosilicates, the particles can electrostatically bind and subsequently 
release therapeutic proteins such as rhBMP2 or TGF-β3 over a prolonged duration. The 
nanosilicates also show high binding capabilities without altering the protein conformation. The 
released proteins were able to maintain high efficacy as demonstrated by in vitro experiments. 




observed compared to exogenous control. Overall, this platform could be easily modified and 
applied to future biomedical applications requiring sustained therapeutic delivery for example 










The bone-cartilage interface is composed of cartilage and subchondral bone, with a gradient in 
structural, physical and chemical properties.(247, 248) For diseases such as osteoarthritis, it is 
difficult to engineer these complex architectures using conventional fabrication technologies to 
facilitate regeneration of damaged tissues. The ability to mimic such interfaces, as well as to 
control the cell-matrix interactions at different locations, will be needed to develop new 
approaches. A range of designs such as layered or gradient structures are developed to mimic 
gradient in structure and mechanical properties.(21, 22) Additionally, the native tissue interface is 
composed of both micro- and nanostructures, making nanoengineered biomaterials an ideal 
scaffold material to mimic the native architecture.(249) A range of nanomaterials are incorporated 
within polymeric networks to improve the structural, mechanical, or biological properties of the 
scaffold. For example, spherical nanoparticles such as nanohydroxyapatite have been extensively 
investigated to mimic the bone-cartilage interface, as it enhances cell proliferation and scaffold 
mechanical properties.(33, 34, 79, 250) 
 
                                                 
* Reproduced with permission “Cross, L.M.; Shah K.; Palani S.; Peak, C.W.; Gaharwar A.K. 
Gradient Nanocomposites for Interface Tissue Engineering. Nanomedicine:NBM, 




Two dimensional (2D) nanomaterials have become a major focus in materials research in many 
applications, including biomedicine. Importantly, they possess the highest specific surface areas 
of all known materials, which is invaluable for applications requiring high levels of surface 
interactions on a small scale. Of these 2D nanomaterials, nanosilicates are uniquely suited for 
orthopedic tissue engineering due to their multiple functions such as ability to mechanically 
reinforce polymeric network, and potential to deliver therapeutic growth factors in a sustained 
manner.(41, 139, 251) Since nanosilicates are composed of complex polyions, they are able to 
interact within a hydrogel and form strong networks which in turn increase the mechanical 
properties.(41, 226, 252) In addition to enhanced mechanical properties, the structure of the 
nanosiliciates allow for increased shear-thinning and thixotropic properties when incorporated into 
polymer solutions.(253, 254) Specifically, nanosilicates independently form noncovalent bonds 
with multiple polymer strands, which can dynamically break and reform during loading, resulting 
in shear-thinning and thixotropic gels. (226, 254) The incorporation of these 2D nanoparticles 
could provide a facile approach in controlling physical and biological properties of the network.  
 
As previously mentioned, most nanocomposite scaffolds for interface tissue are either layered or 
gradient designs.(21, 22) Layered or stratified scaffolds are the most commonly explored, as these 
designs often incorporate multiple materials and cell types to mimic the distinct tissue regions.(58) 
Although the layered scaffolds can account for the different layers of the tissue, i.e. the cartilage 
and subchondral bone, and possibly the interface region, they are susceptible to delamination 
because the layers are not necessarily connected. Alternatively, gradient scaffold designs can 
mimic the gradual change in the physical and mechanical properties that are present at the native 




two tissue regions and have the potential to mimic the natural structural and mechanical gradients. 
(249, 255)  
 
Gradient scaffolds have been fabricated using a variety of materials such as hydrogels and 
nanofibers and fabrication methods including gradient makers, microfluidics, and 
electrospinning.(16) Electrospun, graded scaffolds have been investigated for the bone-cartilage 
interface; however, the fibrous structure does not ideally mimic the cartilage region.(46) 
Alternatively, hydrogel systems have been extensively studied for tissue regeneration due to their 
tunability and cell microenvironment mimicking capabilities and therefore are also ideal for 
gradient scaffolds.(256) Specifically for bone and cartilage tissues, previous studies have reported 
the use of natural material-based hydrogels to support regeneration. For example, gelatin 
methacrylamide (GelMA) has been investigated for bone regeneration, while methacrylated kappa 
carrageenan (MκCA) has been investigated for cartilage regeneration.(41, 250) Although 
microfluidic methods have been investigated for gradient formation with hydrogels, a simpler 
approach utilizing capillary flow was previously introduced which allowed for multi-layer gradient 
hydrogels to be fabricated.(257, 258)  
 
Here, using 2D nanosilicates with two natural polymers, gelatin and kappa carrageenan (kCA), we 
developed a facile approach to fabricate a nanocomposite gradient hydrogel. Gradient hydrogels 
were fabricated using the natural material flow properties, which were enhanced by the addition 
of nanosilicates. A gradient in structure as well as mechanical properties was obtained. In addition, 
cell morphology was controlled along the scaffold. This simple and reproducible gradient hydrogel 






5.2.1 Polymer Solution Synthesis 
Gelatin (type A, from porcine skin) and methacrylic anhydride (MA) were purchased from Sigma-
Aldrich, USA. The synthetic nanosilicates (Laponite-XLG), were obtained from Southern Clay 
Product Inc, USA and the kappa-carrageenan was purchased from Tokyo Chemical Industry (TCI), 
USA. Gelatin methacrylamide (GelMA, 80% methacrylated) and methacrylated kappa-
carrageenan (MκCA, 10% methacrylated) were synthesized using previously published 
methods.(41, 250, 251) Different prepolymer solutions were prepared in deionized water using 
GelMA (5 %wt/v) and MκCA (1 %wt/v) with varying concentrations of nanosilicates (0, 0.25, 0.5, 
0.75 and 1.0 %wt/v). Photoinitiator (IRGACURE 2959, 0.25 %wt/v) was added to the prepolymer 
solutions. The pre-polymer solutions were prepared via vigorous agitation and heated at 37°C for 
15 minutes and were fabricated via UV crosslinking (6.09 mW/cm2, 60 seconds). 
 
5.2.2 Rheology Testing 
Rheological properties were characterized for gelation kinetics and shear stress sweeps using 
DHR-2 Rheometer (TA Instruments). Gelation kinetics of prepolymer solutions under UV 
irradiation was investigated using a 10 mm parallel plate geometry at a gap of 0.3mm. Oscillatory 
stress sweeps from 0.1 and 10 Pa at 1 Hz were carried out on all formed hydrogels. The change in 
viscosity of prepolymer solutions (5% wt/v GelMA and 1% wt/v MκCA, both with and without 
0.5% wt/v nanosilicates) were investigated. Samples were pipetted onto a Peltier plate surface and 
allowed to rest before a 40 mm parallel plate geometry was used to vary the shear rate between 





5.2.3 Gradient Hydrogel Fabrication and Optimization 
Gradient hydrogels were fabricated using machined Teflon molds (15.50 mm x 6.20 mm), 
containing three rectangular wells of dimensions 10x2x1 mm. Two different prepolymer solutions 
of equal volume were pipetted into the either side of the well simultaneously (Figure 5-1). Upon 
UV exposure (6.9 mW/cm2, 60 secs), the prepolymer solutions were crosslinked to obtain a 
covalently crosslinked network. Prior to hydrogel formation, the prepolymer solutions were kept 
in the oven at 37°C. To form uniform gradients, the optimal volume of the prepolymer solutions, 
as well as the optimal time prior to crosslinking to allow for diffusion were determined. GelMA 
stained with Rhodamine B and MκCA prepolymers were used and the solutions remained at 37°C 
until pipetted into the well. For determining the optimal prepolymer volume, three different 
volumes were tested: 5μL, 10μL, and 15μL. Using the optimal volume, the optimal time prior to 
crosslinking was tested at 0, 5, and 10 minutes. At time 0, the solutions were added and the mold 
was immediately exposed to UV. For the other time points, the solutions were added and the mold 
was placed in the oven at 37°C for 5, or 10 minutes and then exposed to UV. Gradient uniformity 
was assessed using ImageJ Plot Profile. 
 
5.2.4 Mechanical Testing 
The compressive stress and modulus of the individual hydrogels were tested using MTESTQuattro 
(ADMENT, USA) with a 25 lb. transducer. The samples were placed in 1X PBS for 1 hour to 
swell prior to testing. Compression tests were performed and carried out to 50% strain. The 
compressive modulus was calculated based on the slope of the linear region from the stress-strain 




using a 2 lb. transducer. To test different regions along the gel, an insert with a 1mm cone head 
was fabricated and prepolymer solutions of varying compositions were prepared (5% wt/v GelMA 
and 1% wt/v MκCA with and without nanosilicates). Six locations along the gradient were probed 
with the 1 mm tip geometry. A MATLAB program was developed to calculate the modulus. 
Statistical analysis was performed using GraphPad Prism. 
 
5.3.5 SEM Characterization 
To characterize the microstructure and porous nature of the gradient hydrogels, a scanning electron 
microscope (SEM) was used (JCM-5000: Benchtop SEM (Neoscope)). The gradient hydrogels 
were fabricated as previously described and then frozen using liquid nitrogen, freeze fractured, 
and lyophilized overnight. The dried samples were then mounted to expose their cross-section and 
sputter coated for 60 seconds at 20 mA with gold. The samples were then viewed with the SEM at 
an accelerating voltage of 10kV. Image analysis was done using ImageJ. 
 
5.3.6 In vitro Cell Studies 
Human mesenchymal stem cells (hMSCs) were cultured in normal growth media (AMEM, 
Hyclone), supplemented with 16.5% FBS (Atlanta Biologicals) and 1% penicillin/streptomycin 
(100U/100 µg/mL; Life Technologies, USA) at 37°C with 5% CO2. Prior to cell encapsulation, 
four Teflon molds were sterilized with 70% ethanol for 15 minutes. Cells were trypsinized, 
neutralized with normal media, and then spun down at 1000 rpm for 5 minutes. Cell pellets were 
resuspended in 80µL of the four prepolymer solutions; there were approximately 100,000 cells in 
each solution. Prepolymer solutions were made in media rather than deionized water and stored at 




pipetted into the Teflon molds and UV-crosslinked (6.9 mW/cm2, 60 seconds). The molds were 
placed into a 24 well plate with normal media. For cell morphology studies at desired time points, 
the molds were washed twice with 1X PBS (Corning) and the samples were fixed using 500 µL of 
2% glutaraldehyde (Sigma Aldrich) for 20 minutes. Samples were then washed with 1X PBS three 
times and 500 µL of 0.1% Triton X-100 in 1X PBS was added to permeabilize the cells for 5 
minutes. Samples were washed with 1X PBS and gels were removed from Teflon molds for 
staining. 100 µL of phalloidin (1:100 dilution in 1%BSA/1XPBS) was added and samples were 
incubated at 37°C and protected from light for 1 hour.  After 1 hour, the stain was removed and 
samples were washed three times with 1X PBS. 100 µL of Propidium Iodine/RNase solution (100 
µg/mL RNASe and 500 nM-1.5 µM Propidium Iodine) was added, incubated at 37°C for 30 
minutes, and then washed three times with 1X PBS. Cell images were taken using a confocal 
microscope (Leica TCS SP5) and images were analyzed with ImageJ. 
 
5.2.7 Statistical Analysis 
The data are plotted as mean and standard deviation. One-way analysis of variance (ANOVA) with 
Tukey’s post-hoc were performed using Graphpad Prism software. Statistical significance 
presented as * p-value<0.05, ** p-value< 0.01, *** p-value<0.001, ****p-value<0.0001.  
 
5.3 Results  
Here we have focused on designing a gradient scaffold for interface tissues as the interface contains 
a gradient in structural, mechanical, and biological properties. Although gradient scaffolds have 
been investigated previously(21, 22, 248, 249), the presented approach for gradient formation 




osteochondral scaffolds have targeted properties such as graded pore size, chemical composition, 
stiffness, or growth factors.(34, 46, 259, 260) Despite the formation of a gradient to match the 
gradual change in native tissue, some of these methods can require intensive materials preparation 
or equipment and only provide a gradual change in one property. In addition, other gradient 
fabrication methods involve complex microfluidic strategies.(261, 262) The presented method is 
simple and with two natural polymers and the inclusion of nanosilicates in the hydrogel network, 
we are able to vary the structural, mechanical, and biological properties of the material.  
 
5.3.1 Nanoengineered Gradient Hydrogels 
Gelatin and κ-carrageenan were ideal polymers for the osteochondral scaffold because of the two 
have been investigated for bone and cartilage scaffolds individually.(41, 250) Gelatin contains 
RGD binding domains which allow for cells to adhere and spread typical of osteoblasts in bone; 
while, kappa carrageenan is a polysaccharide resembling native glycosaminoglycans with limited 
binding sites, and cells will exhibit a more rounded morphology indicative of chondrocytes in 
cartilage.(263, 264) In addition, previous studies have demonstrated the mixing capabilities of 
gelatin and κ-carrageenan in a solution, supporting the mixing of the two solutions in the present 
gradient hydrogel formation.(265) In the present study, these polymers were successfully modified 
with methacrylic anhydride to allow for uniform photopolymerization and hydrogel formation. 
Nanosilicates were incorporated in the two solutions, as previous studies(41, 250) have supported 
increased shear-thinning and therefore increased flow properties as well as their ability to enhance 
the structural properties of a material. Specifically for gelatin, as a polyampholytic natural polymer 
containing both negative and positive regions, it strongly interacts with the opposite charged 




osteochondral regeneration, have not incorporated nanomaterials into both regions of the scaffold 
for increased mechanical stability. Finally, human mesenchymal stem cells (hMSCs) were 
encapsulated within the hydrogel matrix to demonstrate the ability to control cell morphology 
along the gradient (Figure 5-1). Here, gradient hydrogels were successfully fabricated using a 
facile and reproducible method of pipetting two prepolymer solutions into a Teflon mold at the 
same time and allowing capillary action to form uniform distributions. Although previous studies 
have demonstrated the ability to form multi-layer gradient hydrogels using capillary flow, here 
with simple modification, we produced a single but connected layer exhibiting a seamless 
transition from one material to the next. In addition, the Teflon mold allowed for three hydrogels 
to be prepared at once for easy replication and the mold fit within a 24-well plate for simple in 








Figure 5-1 Nanoengineered gradient scaffolds loaded with 2D nanosilicates. Schematic showing formation 
of gradient hydrogel from GelMA and MκCA prepolymers reinforced with nanosilicates (nSi). Cells can 
be encapsulated during the formation of gradient scaffold. The gradient structure is subjected to UV light 
to obtain fully crosslinked scaffold. The GelMA contains cell binding sites which allow for cell spreading, 




5.3.2 Nanosilicate Reinforces Polymeric Network 
Prior to gradient hydrogel formation, the optimum concentration of nanosilicates within the 5.0% 
wt/v GelMA and 1.0% wt/v MκCA hydrogels for improved mechanical properties was determined 
through compressive mechanical tests (Figure 5-2). The concentrations of 5.0% wt/v GelMA and 
1.0% wt/v MκCA were chosen based on previous studies.(41, 250) The addition of the 
nanosilicates significantly increased the compressive moduli and strength of the gelatin and κ-




hydrogels increased up to seven-fold with the addition of 1% wt/v nanosilicates, while the strength 
of the MκCA hydrogels increased nearly three-fold at the same concentration. Similarly, with 0.5% 
wt/v nanosilicates, the strength of GelMA hydrogels increased three-fold while MκCA hydrogels 
increased two-fold. It was determined that the addition of 0.5% wt/v nanosilicates was the optimal 
concentration since it provided a significant increase in the MκCA hydrogels’ compressive moduli 
(2.4±0.3 kPa to 3.4±0.5 kPa) without increasing the mechanical properties so much that it would 
mimic the GelMA hydrogels’ mechanical properties too closely (Figure 5-2b). In addition, rather 
than incorporating another variable to the study, 0.5%wt/v nanosilicates was chosen for the GelMA 
region as well. Although the addition of 0.5%wt/v nanosilicates was not statistically different from 
GelMA hydrogels without nanosilicates, the modulus was still increased two-fold (from 3.5±0.6 








Figure 5-2 Nanosilicates reinforce the polymeric hydrogels. Uniaxial compression test shows that addition 
of nanosilicates to (A) GelMA and (B) MκCA hydrogel results in an increase in compressive modulus. 
(Statistical analysis: One-way ANOVA with Tukey’s post-hoc analysis, *P-value < 0.05, **P-value < 0.01, 




5.3.3 Nanosilicates Modulate Flow Properties and Rheological Characteristics 
With these optimal concentrations, the flow properties of the prepolymer solutions were 
investigated to evaluate flow once pipetted into the molds. To investigate the effect of nanosilicates 
on the shear-thinning behavior of prepolymer solutions, the viscosity at different shear rates (0.01-
100 1/s) was monitored (Figure 5-3a). The viscosity decreased with increasing shear rate for all 
prepolymer compositions suggesting shear-thinning behavior; however, depending on the 
backbone chemistry and the inclusion of nanosilicates, viscosity can be modulated. Addition of 
0.5% wt/v nanosilicates generally causes a solution to have an increase in its shear-thinning ability 




increased the shear-thinning behavior of the prepolymer solutions. Although MκCA nSi was 
observed to have the highest viscosity, the solution still flowed through the mold.  
 
The gelation kinetics as well as the structural stability of hydrogels at these final concentrations 
were also investigated (Figure 5-3b). Methacrylate functional groups on both gelatin and kappa 
carrageenan permitted covalent crosslinking through UV-initiated free radical polymerization. The 
addition of nanosilicates did not affect the gelation time of either the GelMA or MκCA hydrogels 
as indicated by the similar plateaus of the storage modulus; however, the storage modulus was 
increased by nearly two-fold in the GelMA hydrogels with the addition of the nanosilicates, 
supporting the increase in mechanical properties seen in compression testing. The rheological data 
support the results observed in compressive tests, and indicate that only a small percentage of 









Figure 5-3 Nanosilicates modulate flow and rheological properties of prepolymer solution. (A) The 
addition of 0.5 % wt/v nSi allowed the GelMA and MκCA prepolymer solutions to exhibit shear-thinning 
behavior, a decrease in viscosity with increasing shear-rate. (B) UV gelation kinetics reveals an increase in 





5.3.4 Optimizing Gradient Hydrogels  
Once the flow properties were determined, the optimal volume to allow each solution to flow 
towards the middle of the channel as well as the optimal time to allow for uniform distribution of 
solutions were determined (Figure 5-4a). Of the three volumes tested, 10 µL of each solution 
enabled equal flow to the middle. In addition, 5 µL of each solution was too small of a volume to 
reach the center, while 15 µL nearly overflowed the channel. This even flow was confirmed with 




provided the pixel density along the distance of the gradient; with increasing distance the pixel 
intensity displayed a sigmoid curve. Using this optimal volume, the ideal time prior to crosslinking 
was observed to be 5 minutes, which allowed for uniform distribution of both solutions. Although 
immediate crosslinking after administration allowed for some flow between solutions, 
quantification with ImageJ revealed a more uniform distribution after 5 minutes (Figure 5-4b). 





Figure 5-4 Fabrication of gradient hydrogels. (A) Optimization of solution volume to form uniform 
gradients revealed 10 µL of each solution allowed for immediate mixing (top). ImageJ quantification 
supported this observation (bottom). (B) Optimal time for uniform mixing of solutions once pipetted was 





5.3.5 Gradient in Structural and Mechanical Properties of Hydrogels  
Characterization of the structural and mechanical properties of the gradient hydrogels with and 




SEM and a distinct change in mesh area was noted when shifting from the GelMA region (4.0 ± 
2.7 µm2) to the interface region (16.9 ± 14.4 µm2) and then to the MκCA region (75.3 ± 49.0 µm2) 
of the scaffold (Figure 5-5a). With the addition of nanosilicates, an increase in mesh area shifting 
from the GelMA-nSi region to the MκCA-nSi region was also observed (Figure 5-5b). Previous 
studies have reported an increase in mesh size in GelMA hydrogels due to interactions of the 
nanosilicates with the gelatin backbone, supporting the increase observed in this study.(41) 
Alternatively, mesh size was previously observed to decrease with the addition of nanosilicates in 
MκCA hydrogels.(250) This discrepancy could result from changes in MκCA and nanosilicate 
concentrations; the concentrations used in this study are smaller than those used in the previous 
study and therefore could affect the way the materials interact together. At the interface regions, a 
range of mesh sizes exists which leads to high standard deviations but demonstrates the integration 
of the two natural polymers.  
 
To characterize the mechanical properties of gradient structures, compression tests were performed 
using a 1mm cone geometry that allowed for different regions along the scaffold to be probed 
(Figure 5-5a,b). For all hydrogels, a total of six regions along the gel were tested. For both 
gradients, a decrease in the compression modulus was observed when shifting from the GelMA 
regions to the MκCA regions, supporting previously observed compressive moduli values for 
individual hydrogels. Specifically, in the hydrogels without nanosilicates, the moduli shifted from 
6.7±0.4 kPa in the GelMA region to 1.8±0.4 kPa in the MκCA region. When nanosilicates were 
incorporated, the moduli decreased from 7.5±1.7 kPa in the GelMA nSi region to 3.6±1.8 kPa in 




1mm cone geometry was validated by testing GelMA hydrogels and resulting moduli values were 





Figure 5-5 Gradient in microstructure and mechanical stiffness of scaffold. (A) Scanning electron 
micrographs of gradient hydrogels (GelMA- MκCA). A significant increase in mesh size was observed at 
the interface and MκCA regions, compared to the GelMA region. Compression testing of gradient 
hydrogels revealed a gradual decrease in compression moduli when shifting from GelMA region to MκCA 
region. (B) The addition of nanosilicates increased the overall gradient hydrogel mesh size with a significant 
increase in the interface and MκCA nSi regions compared to the GelMA nSi region. Similarly, mechanical 
testing revealed a gradual decrease in compressive moduli but the inclusion of nSi increased the overall 
compressive moduli two-fold (Statistical analysis: One-way ANOVA with Tukey’s post-hoc analysis, *P-




5.3.6 hMSC Encapsulation Exhibits Gradient in Cell Morphology 
The cellular response at different regions of the gradient hydrogels was investigated through 3D 
encapsulation of human mesenchymal stem cells (hMSCs) (Figure 5-6a). hMSCs were 
successfully encapsulated within the hydrogel networks and imaged after one and three days. After 
one day, cells remained round in all regions of both gradient scaffolds. However, after three days 




the gradient. In the GelMA and GelMA-nSi regions, cells were spread out characteristic of 
osteoblasts in bone, while the MκCA and MκCA-nSi regions, cells exhibited a round morphology 
characteristic of chondrocytes in cartilage.(267) At the interface regions, both cell morphologies 
were present, indicating a smooth transition from one region to the next (Figure 5-6b). These 
results reinforce previous studies that suggest GelMA and MκCA to support bone and cartilage 
regeneration respectively.(41, 250)  
 
Average cell circularity and cell area along the scaffold were calculated using ImageJ to quantify 
these changes in cell morphology (Figure 5-6c,d). Circularity (a.u) ranged from 0-1, in which 1 
represented a perfect circle. In the GelMA region, the average cell circularity was found to be 0.4 
± 0.2 while in the MκCA region this increased significantly to 0.8 ± 0.1. At the interface, the 
average cell circularity was 0.5 ± 0.3, in between the average for the two extreme regions of the 
scaffold. With the addition of nanosilicates, the average cell circularity was not significantly 
affected; however, a similar trend in cell circularity was observed from the GelMA nSi region to 








Figure 5-6 Gradient in cell adhesion and morphology. (A) Schematic demonstrating change in cell 
morphology along gradient hydrogel. As the cell adhesion sites decrease, the cell morphology becomes 
rounder. (B) Increased cell spreading was observed in the GelMA nSi region after three days of culture 
while in the MκCA nSi region, cell morphology remained significantly round. At the interface region, both 
cell morphologies were present. (C) Cell area decreased along the gradient scaffold from the GelMA to the 
MκCA region. The addition of nanosilicates increased the cell area in the GelMA region while its inclusion 
did not significantly affect the cell area in the MκCA or interface regions. (D) Similarly, cell circularity 
was much greater in the MκCA regions compared to the GelMA regions where cells were observed to be 
more spread out. (Statistical analysis: One-way ANOVA with Tukey’s post-hoc analysis, *P-value < 0.05, 




In addition to circularity, the average cell area along the gradient scaffolds was calculated. Average 




the interface region (656.9 ± 300.1 µm2) and to the MκCA region (431.3 ± 169.5 µm2) where cells 
were more rounded (Figure 5-6c). When nanosilicates were incorporated into the scaffold, average 
cell area was not significantly affected but a similar trend existed.  
 
5.4 Discussion 
Gradient scaffolds were successfully fabricated utilizing gelatin, κ-carrageenan, and nanosilicates 
in a facile microfabrication process. Previously, gelatin and κ-carrageenan have shown to mix well 
in solution, supporting the ability to form a gradient.(265, 268) In addition, once in solution 
together, the polymers interact with one another via electrostatic interactions.(268) These initial 
interactions may allow for the solutions to be loosely bound prior to UV crosslinking and further 
enhance the connectivity of the scaffold. Additionally, incorporation of nanosilicates with these 
two natural materials have previously shown to enhance shear-thinning characteristics as well as 
structural and mechanical properties via electrostatic interactions.(41, 250) Structural, mechanical, 
and biological gradients were successfully generated in the micro-fabricated scaffolds utilizing 
these natural polymers and nanosilicates. 
 
Investigating the microstructures of the gradient hydrogels via SEM revealed a gradient in the 
structure, specifically with the changes in mesh size. Mesh size is important for nutrient diffusion 
as well as cell infiltration in the scaffold.(269) For bone regeneration, some studies have reported 
optimal mesh sizes around 100 µm, while others have suggested lower pore size around 16 µm to 
support osteogenesis.(270, 271) In the present study, the mesh size of the GelMA regions of the 
scaffold fall within this smaller range; however, previous studies investigating GelMA for bone 




regeneration, a previous study suggested mesh size within the range of 50 to 500 µm to support 
chondrogenensis and as the mesh size increased, cartilage specific markers increased.(272) Here, 
the mesh size of MκCA fell within this range. Overall, the observed increase in mesh area across 
the hydrogels indicated the formation of a structural gradient in the two scaffolds. This gradient in 
mesh size could promote cell differentiation along the scaffold for bone-cartilage regeneration. 
 
In addition, a gradient in mechanical properties was observed across the scaffold via compression 
tests. Although a gradual change in moduli was observed, high error was still present in some of 
the samples as a result of the small sample and sample geometry. In addition, achieving 
reproducibility in the six regions tested along the gradient hydrogel was difficult. Regardless of 
these difficulties, a distinct transition in the mechanical properties of both gradient hydrogels was 
observed indicating successful fabrication of a gradient in mechanical properties. As previously 
discussed, hydrogel stiffness can be influential in directing cell morphology and possibly cell 
differentiation.(273, 274) With the present gradient in the nanocomposite’s mechanical properties, 
the scaffold holds the potential to further stimulate cell morphology and subsequently cell 
differentiation along the different regions. 
 
Finally, encapsulated hMSCs demonstrated a gradient in the biological properties of the scaffold, 
specifically through observation of changes in cell morphology along the gradient.  Although the 
standard deviation in average cell area was high in the GelMA and interface regions with and 
without nanosilicates, this is most likely a result of the projection of images required to obtain a 
clean image with encapsulated cells which then layered cells over one another making it difficult 




regions contained cells exhibiting spread morphologies, some round cells were still present, 
bringing down the average area and increasing the standard deviation. Unfortunately, the role of 
nanosilicates in directing cell morphology was not as pronounced at the low chosen concentration 
even though the addition significantly affected mechanical properties of the scaffold. These cell 
encapsulation studies indicated the ability to control cell morphology along a gradient scaffold. 
Although cell differentiation was not investigated in this study, this change in cell shape along the 
nanocomposite implies the potential for controlling cell fate. More importantly, cell morphology 
was controlled with just the material selection and incorporation of nanosilicates. 
 
5.5 Conclusion 
Overall, in this study we have introduced a simple and reproducible approach for fabricating 
nanocomposite gradient hydrogels. The inclusion of nanosilicates, a novel 2D nanomaterial, 
allowed for control over the structural, mechanical, and biological properties. Specifically, the 
structural and mechanical properties of the gradient hydrogel were characterized demonstrating 
the ability to vary these properties through material selection and generate a gradient in these 
physical properties. In addition, successful cell encapsulation and control over cell morphology 
demonstrates the potential to direct cell fate within the network and possibly direct cell 
differentiation without the use of growth factors. This simple approach could be applied to 
regeneration of the bone-cartilage interface where a natural gradient in the structural, mechanical, 






6. FUTURE RECOMMENDATIONS 
 
 
The preceding studies have demonstrated the versatility of nanosilicates in modulating 
differentiation of human mesenchymal stem cell towards osteogenic and chondrogenic lineages, 
delivering protein therapeutics for prolonged duration, and reinforcing tissue engineered 
constructs for tissue engineering. While the studies provide strong potential of nanosilicates for 
replacing standard bioactive cues, the present work also presents several future avenues for the 
field of orthopedic tissue regeneration.  
 
Here we have shown that nanosilicates stimulate osteogenic and chondrogenic differentiation in 
hMSCs using whole-transcriptome sequencing (RNA-seq). Using a biology or bioinformatics 
perspective, we were able to utilize a technique that has had limited use in the field of biomedical 
engineering. Along the same lines, future work could incorporate other bioinformatics techniques 
including proteomics and metabolomics and integrate this data with transcriptomics. The 
incorporation and correlation of these datasets via multi-omics would provide a more complete 
understanding of phenotypic changes to hMSCs. While multi-omics approaches have been 
recently investigated for understanding different diseases including cancer,(275, 276) they have 
not yet been incorporated into tissue or regenerative engineering strategies. In particular, this 
integrative approach has the potential to help further predict cellular responses to nanomaterials 
via a system-wide overview of regulatory processes. By probing multiple levels of molecular 
mechanisms, we can better predict and narrow down specific genetic targets of nanosilicates or 




production as mRNA found through transcriptomics is not always translated to protein.(277) In 
addition, metabolomics could provide more information on cellular physiology as metabolites are 
considered to be cellular processes end products.(278) The integration of these data sets could 
provide a more holistic view of cellular phenotype and function after treatment with nanoparticles 
such as nanosilicates and allow for predicting future alternatives to traditional bioactive cues in 
regenerative engineering.  
 
In this work, we investigate the effect of nanosilicate dissolution products (Li+, Mg2+, Si(OH)4) on 
hMSC osteogenic differentiation. Protein production and some gene expression data support the 
role of individual ions on osteogenic differentiation, however, future RNA-sequencing of 
individual ions will provide greater insight on specific genes affected. For example, previous 
studies have suggested lithium ions to upregulate Wnt responsive genes via elevating cytosolic β-
catenin.(164, 203) Silicon and magnesium ions have also been reported to stimulate collagen I 
formation and enhance bone cell adhesion, respectively.(161, 204) In addition to stimulating 
osteogenesis or promoting bone formation, other ions including copper and silicon have shown to 
promote angiogenesis.(279, 280) Using RNA-seq to elucidate genetic changes to hMSCs after 
treatment with ions such as these will allow us to map specific pathways regulated by these ions. 
We expect to observe pathways such as Wnt, MAPK, VEGF and/or IGF signaling.(201, 281) 
Importantly, we can begin to create libraries of ions and genetic targets that will help design novel 
mineral-based nanoparticles for specific tissue regeneration strategies. 
 
In addition, while our results support the ion dissolution products of nanosilicates help stimulate 




Future studies could investigate this as the nanosilicates or nanoclays used in this work are also 
available in different sizes and with different ion compositions. The size of the particle could affect 
cellular uptake as it has been shown that certain endocytosis mechanisms are dependent on particle 
size.(239) In addition, the nanoparticle composition or ion makeup could affect the surface charge 
which dictates protein adsorption or protein corona formation and could subsequently affect 
surface receptors the nanoparticle binds to, affecting downstream signaling processes.(165, 237). 
Investigating different ion compositions could also result in different hMSC responses because 
nanoparticle dissociation or ion dissolution could stimulate different genes and pathways. It would 
be interesting to investigate the transcriptional changes to human mesenchymal stem cells with the 
addition of these different particle sizes, shapes, and compositions and compare the effects. 
Comparing genetic changes after treatment with different nanosilicates could provide greater 
insight on shape/size/composition effects on modulating hMSC behavior and differentiation. 
Genes differentially regulated across all nanosilicates tested could be identified and particles 
stimulating specific pathways such as differentiation could also be found, helping to narrow down 
which attributes of the particle are dictating certain processes. In addition, to investigate 
intracellular delivery of the ions that makeup the nanosilicates used in the previous studies, the 
ions could be encapsulated into a PLGA nanoparticles and delivered to hMSCs. This would allow 
for comparison of how much the physical characteristics of the particle dictate cellular responses 
compared to the chemical composition.  
 
In addition, in this work, we demonstrate the ability of nanosilicates to act as a therapeutic delivery 
vehicle for osteogenic differentiation in hMSCs. These studies are very promising and present the 




could incorporate this system into an injectable hydrogel or even a pre-established material such 
as the collagen sponges used in Medronic’s Infuse® Bone Graft. Rather than soaking the sponges 
in a solution of rhBMP2, the sponge could easily be soaked in a solution of nanosilicates with 
bound rhBMP2. Not only could the concentration of rhBMP2 be significantly reduced since the 
nanosilicates can sustain release, but also the innate osteoinductivity of nanosilicates could 
improve bone regeneration.  
 
Along the same lines, future studies could incorporate low concentrations of growth factors into 
the gradient hydrogel presented in Chapter 5. Specifically, rhBMP2 could be bound to 
nanosilicates before incorporation into GelMA for the bone region and TGF-β could be bound to 
nanosilicates before incorporation into MκCA for the cartilage region. hMSC differentiation could 
then be monitored along the gradient. A potential problem with MκCA is that it has a high swelling 
degree which could lead to a burst release of the incorporated growth factor. However, 
incorporation of nanosilicates has shown to reduce swelling and binding of TGF-β to the 
nanosilicates prior to incorporation into MκCA should prolong release of the growth factor. In 
addition, the work presented here demonstrates that nanosilicates can induce both osteogenesis 
and chondrogenesis so incorporation of low dosages of growth factor for both bone and cartilage 
along with the nanosilicates should also enable hMSC differentiation. While the current system is 
a good platform to demonstrate the ability to form a gradient in structural and mechanical 
properties as well as cell morphology using these materials, this system is not necessarily 
translatable to implantation in vivo. Therefore, future studies could optimize this system to 













Through this work we have demonstrated the unique biomedical capabilities of nanosilicates 
(Laponite XLG), specifically for regeneration of orthopedic tissues such as bone and cartilage. In 
particular, we have developed a nanosilicate-based platform that can (a) stimulate hMSC 
osteogenic and chondrogenic differentiation without external growth factors, (b) act as a delivery 
vehicle for sustained and localized delivery of therapeutic growth factors as well as augment 
differentiation, and (c) be incorporated into a hydrogel composite to aid in bone-cartilage tissue 
regeneration.  
 
In Study 1, “Two-Dimensional Nanosilicates Stimulate and Modulate Human Mesenchymal Stem 
Cells,” Utilizing RNA-sequencing, hMSCs after treatment with nanosilicates were investigated at 
the whole-transcriptome level to gain a holistic understanding of nanosilicate-hMSC interactions. 
Nanosilicates significantly and differentially regulated over 4,000 genes compared to untreated 
hMSCs and activated key cellular pathways including MAPK signaling. Importantly, genes and 
pathways related to both osteogenic and chondrogenic differentiation were also significantly 
regulated, highlighting the potential for the use of this nanomaterial in regenerative engineering 
strategies. While researchers have used RNA-seq in other fields to investigate changes at the 
transcriptome level in cancer for example, this approach for predicting genetic targets of 





To further investigate mechanisms of nanosilicates innate bioactivity, in Study 2, “Mineral 
Nanoparticle Dissociation Influences Human Mesenchymal Stem Cell Osteogenic 
Differentiation,” nanosilicate dissociation into their individual ions (Li+, Mg2+, and Si(OH)4) at 
physiological pH was evaluated. Using ICP-MS, significant dissociation was observed at 
extracellular (~7.4) and intracellular (~5.5) pH. hMSC viability after treatment with various 
concentrations of ions was monitored and importantly the concentration of ions, even if 100% 
dissociation was achieved, fell within a safe and viable concentration range. hMSCs were treated 
with concentrations observed in dissociation and osteogenic differentiation was evaluated, 
revealing the role of these individual ions in differentiation. While an increase in osteo-specific 
proteins and genes were observed with the individual ions, the combination of all three ions 
revealed the most similar increase to nanosilicates, supporting the delivery within one particle. 
Investigating the individual minerals, however, did provide insight into pathways that are 
stimulated and provides valuable information for future studies to design specific mineral-based 
nanoparticles to direct hMSC differentiation. In addition, future whole transcriptome sequencing 
of hMSCs after individual ion treatment will uncover more specific genes and pathways.  
 
In Study 3, “Localized Therapeutic Delivery from 2D Nanosilicates Directs Differentiation of 
Human Mesenchymal Stem Cells,” nanosilicates were utilized as a delivery vehicle to localize 
rhBMP2 and TGF-β3 to hMSCs. The unique physical properties of nanosilicates, namely their dual 
charge, allow for a variety of interactions with proteins and small molecules. Nanosilicate-protein 
interactions were evaluated and their ability to bind and release proteins overtime were 
demonstrated. Nanosilicates were used to deliver therapeutic and safe concentrations of bone 




osteogenic and chondrogenic differentiation were evaluated respectively and compared to hMSCs 
treated with exogenous growth factor. Importantly, hMSCs treated once with nanosilicate/growth 
factor expressed greater differentiation than hMSCs treated repeatedly with exogenous growth 
factor, demonstrating the ability of nanosilicates to sustain and localize therapeutic delivery. In 
addition, nanosilicates allowed for delivering significantly lower concentrations of growth factor 
compared to other studies. Nanosilicates can act as a delivery vehicle for future tissue engineering 
strategies to reduce the concentration of growth factors necessary for successful regeneration.  
 
Finally, in Study 4, “Gradient Nanocomposite Hydrogels for Interface Tissue Engineering,” 
nanosilicates were incorporated into natural materials (GelMA and MκCA) and a gradient 
hydrogel was fabricated for potential bone and cartilage interface tissue regeneration. Material 
selection and characterization was performed to optimize the concentration of materials in the final 
composite. In addition, optimization of gradient hydrogel formation was done to ensure sufficient 
mixing of the two materials. Successful fabrication of gradient hydrogels was completed and a 
gradient in structural and mechanical properties was demonstrated. hMSCs were encapsulated 
within the gradient hydrogels and cell morphology was assessed, revealing increased spreading in 
the GelMA regions whereas the MκCA region exhibited limited spreading due to lack of cell 
binding motifs. Importantly, this gradation in cell morphology mimics the native bone-cartilage 
interface where different cell morphologies are present; specifically, in native bone, cells are 
spread whereas in native cartilage, cells have a more rounded morphology. This facile fabrication 






These works demonstrate the capabilities of nanosilicates as an alternative bioactive nanomaterial 
that has great potential in the field of tissue or regenerative engineering. Utilizing the unique 
biochemical and biophysical properties of nanosilicates, a platform was designed. While in this 
work we mainly utilize this platform to investigate bone regeneration, RNA-sequencing uncovered 
other differentiation pathways including chondrogenesis and angiogenesis. As a result, 
nanosilicates could be utilized to deliver other growth factors including vascular endothelial 
growth factor (VEGF) for enhancing vascularization. In addition, nanosilicates can be incorporated 
into a variety of polymers or hydrogels for different tissue engineering applications.  
 
In order to develop and test new bioactive materials for tissue engineering, we can borrow 
techniques from other science and engineering fields. Here we have leveraged RNA-sequencing 
to uncover genetic changes to hMSCs after treatment with one nanomaterial, nanosilicates. This 
technique holds great potential for future nanomaterials and can help predict the regenerative 
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Figure A-1 RNA-seq data analysis. (A) Distribution of log2(RPKM + 0.01) of all genes. (B) MA plot 
(Bland-Altman plat) for all genes that are tested by the RPKM > 1 cutoff. (C) Replicate variation of RNA-
Seq samples. Correlation for replicates among untreated and treated populations, respectively, indicate high 
degrees of reliability and consistency between tested samples. (D) Broad grouping of GO terms into three 
main groups: biological processes, cellular component, and molecular function. (E) GO terms specific to 
endocytosis process. (F) PCR validation of RNA-seq specific to gene controlling clathrin machinery 








Figure A-2 (A) Network of GO terms and expressed gene clusters around each respective correlating term 
illustrating highly interconnected stimulation with nanosilicates. (B) GO terms could be subsequently 
divided into four primary cellular systems including basic processes, membrane organization, kinase 
signaling, and differentiation responses. (C) Gene network displaying interconnected genetic targets after 
nanosilicate treatment with high degrees of expression and statistical significance (red, up-regulated; green, 








Figure A-3 (A) Kegg pathway specific to MAPK signaling with differentially expressed genes form RNA-
seq (red, up-regulated; blue, down-regulated). (B) Organization of gene expression throughout MAPK 
















Figure A-5 (A) Expression tracks for collagen type I (COL1A1) for control (blue) and treated (red) 
populations. (B) Western blot for differentiation-specific proteins, COMP, for control and nanosilicate-
treated samples. Addition of MEK inhibitor reduced protein synthesis of both targets. *P < 0.05; ***P < 
0.001. ns, not significant.  
 
 
 
